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Introduction 
 Medicinal chemistry is branch of pharmaceutical chemistry, which deals with 
design, chemical synthesis & development for market of pharmaceutical agents 
(drugs). 
 Drug design is a repeat process which begins when a chemist identifies a 
compound that displays an interesting biological profile and ends when both the 
activity profile and the chemical synthesis of the new chemical entity are optimized. 
Traditional methods to drug discovery rely on a step-wise synthesis and screening 
program for large numbers of compounds to optimize activity profiles. Past few 
decades, scientists have used computer models of new chemical entities to help define 
activity at molecular level. 
 Dihydropyridines (DHPs) represent a group of small organic compounds 
consist of  pyridine core. Theoretically, five isomeric DHPs can exist, among that the 
recognized DHPs have either the 1,2-dihydro or the 1,4-dihydro structure. DHPs have 
a wide  range of pharmacological actions as agents in vasodilation, bronchodilation, 
hepatoprotection and geroprotection and as antiatherosclerosis, antidiabetes, 
antitumor, antimutagenic, antioxidant, anticonvulsant and antiradical agents . 
Dexniguldipine is a chemosensitizer with low hypotensive properties. It is clear that 
the new generation of DHP derivatives are a potential source of valuable drug 
candidates with remarkable potential and ongoing interest. 
General Method of synthesis of  1,4 DHP Synthesis 
 The Hantzsch pyridine synthesis or Hantzsch dihydropyridine synthesis is a 
multi-component organic reaction between an aldehyde such as formaldehyde, 2 
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equivalents of a β-keto ester such as ethyl acetoacetate and a nitrogen donor such as 
ammonium acetate or ammonia. 
Mechanism of the Hantzsch Dihydropyridine Synthesis 
The reaction can be visualized as proceeding through a Knoevenagel Condensation 
product as a key intermediate: 
 
A second key intermediate is an ester enamine, which is produced by condensation of 
the second equivalent of the β-ketoester with ammonia: 
 
Further condensation between these two fragments gives the dihydropyridine 
derivative: 
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Molecular Modeling 
One of the basic tenets of medicinal chemistry is that biological activity is 
dependent on the three-dimensional placement of specific functional groups (the 
pharmacophore). Over the past few years, advances in the development of new 
mathematical models which describe new molecules and development of more 
intuitive program interfaces coupled with the availability of faster, smaller and 
affordable computer hardware have provided experimental scientists with a new set of 
computational tools. These tools are being successfully used, in conjunction with 
traditional research techniques, to examine the structural properties of existing 
compounds, develop and quantify a hypothesis which relates these properties to 
observed activity and utilize these "rules" to predict properties and activities for new 
chemical entities. The development of molecular modeling programs and their 
application in pharmaceutical research has been formalized as a field of study known 
as computer assisted drug design (CADD) or computer assisted molecular design 
(CAMD). 
 Computational chemistry molecular modeling is the science (or) art of 
representing molecular structures numerically and simulating their behavior with the 
equations of quantum and classical physics. Computational chemistry programs allow 
scientists to generate and present molecular data including geometries (bond lengths, 
bond angles, torsion angles), energies (heat of formation, activation energy, etc.), 
electronic properties (moments, charges, ionization potential, electron affinity), 
spectroscopic properties (vibrational modes, chemical shifts) and bulk properties 
(volumes, surface areas, diffusion, viscosity, etc.). As with all models however, the 
chemist's intuition and training is necessary to interpret the results appropriately. 
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Comparison to experimental data, where available, is also important to guide both 
laboratory and computational work. 
Hit to Lead, and Lead Optimization 
Further chemistry and analysis is necessary, first to identify and sorting 
compounds that do not provide series displaying suitable SAR and chemical 
characteristics associated with long-term potential for development, then to improve 
remaining hit series with regard to the desired primary activity, as well as secondary 
activities and physiochemical properties such that the agent will be useful when 
administered in real patients. In this regard, chemical modifications can improve the 
recognition and binding geometries (pharmacophores) of the candidate compounds, 
and so their affinities for their targets, as well as improving the physicochemical 
properties of the molecule that underlie necessary pharmacokinetic/pharmacodynamic 
(PK/PD), and toxicology profiles (stability toward metabolic degradation, lack of 
geno, hepatic, and cardiac toxicities, etc.) such that the chemical compound or 
biologic is suitable for introduction into animal and human studies. 
Drug design parameter 
 Lipinski's Rule of Five is a set of principles that to evaluate drug likeness, or 
determine if a chemical compound with a certain pharmacological or biological 
activity has properties that would make it a likely orally active drug in humans. The 
rule was formulated by Christopher A. Lipinski in 1997, based on the observation that 
most medication drugs are relatively small and lipophilic molecules.  
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 This  rule describes molecular properties important for a drugs 
pharmacokinetics in the human body, including their absorption, distribution, 
metabolism, and excretion ("ADME"). However, the rule does not predict if a 
compound is pharmacologically active. 
 The rule is important for drug development where a pharmacologically active 
lead structure is optimized step-wise for increased activity and selectivity, as well as 
drug-like properties as described by Lipinski's rule.  
 Lipinski's rule says that, in general, an orally active drug has no more than one 
violation of the following criteria: 
• Not more than 5 hydrogen bond donors (nitrogen or oxygen atoms with one or        
      more hydrogen atoms) 
• Not more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms)  
• A molecular mass not greater than 500 daltons. 
• An octanol-water partition coefficient log P not greater than 5.  
QSAR of 1, 4 DHP  
 The DHPs  a group of  compounds has been the aim of many quantitative 
structure–activity relationship (QSAR) studies to find the most important quantitative 
parameter for optimal activity of these compounds. The Hansch analysis method to a 
series of 4-phenyl-substituted DHPs. They concluded that the biological activity of 
DHPs is dependent on the lipophilic, as well as the electronic and steric properties, of 
the substituent on 4-phenyl DHP analogs of nifedipine. Hansch analysis on a small 
number of the same DHPs and found that bulky and lipophilic groups at the ortho-
position and bulky groups with high Hammet electronic constant (s) at the meta-
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position of the 4-phenyl ring increase the DHPs’ activity. They also concluded that 
the potency of DHPs decreases with the increase in minimum width or length of 
substituents at the para-position, and optimal values were found to be those for 
hydrogen. They found that the activity of meta-substituted compounds is affected by 
both steric and electronic parameters, whereas the hydrophobic and electronic 
parameters of the para-substituted DHPs affect the drug’s activity. Hansch analysis 
for those nifedipine analogs containing nitroimidazolyl, phenylimidazolyl and 
methylsulphonylimidazolyl groups at the C-4 position and different ester substituents 
at C-3 and C-5 positions of DHP ring and showed that Hammett’s electronic and 
hydrophobic properties are highly correlated with the biological activity. Different 
linear and nonlinear methods have been used in QSAR studies (Non-3D, also known 
as classical QSAR) of DHP analogs to get additional and more precise parameters that 
are important for the biological activity of these compounds. Partial least squares and 
principal component artificial neural network were employed, using theoretically 
derived descriptors for different DHP analogs. In addition, the quantum chemical 
QSAR study of these compounds indicated the importance of electronic features of 
the DHP derivatives for receptor binding. Compared with classical QSAR 
investigations, 3D QSAR approaches yield better results for the correlation of the 
internal dataset and prediction of test set DHP derivatives. Different 3D QSAR 
approaches have been conducted to simplify the design of optimized DHP derivatives 
with increased calcium antagonist activity. 3D QSAR study-COMFA of 4-phenyl-
substituted DHPs indicates unfavuorable steric interactions for bulky moieties in the 
para-position of the phenyl ring and that bulky substituents are favorable in ortho- and 
meta-positions. The best combination is obtained when the bulky substituent at ortho 
or meta produce negatively charged electrostatic potential. In addition, this study 
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indicated that repulsive electronic interaction with binding-site residue or to the 
potential of electron-deficient 4-aryl moieties behave as electron acceptors in charge 
transfer mechanism. 
 
Diabetes 
        Diabetes is not a disease but a disorder, affecting 10% of the human 
population where the body does not produce insulin or does not properly use insulin 
due to which the glucose concentration remains high in the blood stream. 
Glucose, Insulin and Diabetes 
   Glucose is derived from all kind of foods that we consume. Pancreas, a small 
gland below the stomach secretes a hormone called insulin. The insulin released 
carries the blood glucose present in the blood stream to cells that need extra energy. 
The cells do not and can not use glucose without the help of insulin. Once inside the 
cells, the glucose produces heat and energy. But if the insulin is not helping, then the 
glucose is not of use to body and in fact it is bad for body to have too much of unused 
glucose. In a normal individual, body manages to maintain a ideal level of glucose 
concentration. But in diabetes insulin is either not produced or not utilized properly, 
and hence the glucose remains in the blood causing the condition “Diabetes”. 
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Types of Diabetes 
Diabetes due to absence of insulin 
       This is frequently seen in childhood and hence called, Juvenile Onset or 
Childhood Diabetes. In this diabetes which is called Type 1, the patient has failed to 
produce insulin and the only remedy to overcome this is to go in for Insulin injections. 
The problem can happen in any age of the individual, though majority are from 
childhood. The injected insulin, the frequency and dose is decided by the medical 
expert. The synthesized insulin is injected and it mimics the natural insulin and the 
individual can lead a normal life. 
Diabetes due to ineffective insulin 
       This is commonly seen in adults and called as Type 2. Though the body produces 
insulin it has trouble using it, that is body is resistant to its own insulin. High blood 
sugar is found in the blood without being transported to the cells. Routine checkups 
with dietary restrictions and healthy life style along with regular affordable physical 
and mental activities are the only solution. There are medicines available which make 
insulin more effective in such individuals and a combination of medicines and calorie 
control can help the patients a lot in keeping the disorder under control. 
Diabetes Management 
       Both types of diabetes have different treatment options and in general population 
the Type 2 diabetes is more prevalent than Type 1. More than 80% of the patients 
have Type 2 which means it is a problem of ineffective insulin. 
       In case of Type 1, the objective of treatment is to give adequate insulin, in right 
intervals so that the patient will not have “Hypo” or “Hyper” sugar levels. This 
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requires frequent monitoring for sugar levels and require higher frequency of medical 
supervision and intervention. 
       In case of Type 2, the objective of treatment is to make insulin more effective and 
reduce the consumption of unwanted food materials. This is achieved by reduction in 
quantity of food or modifications in type of food, increase in physical exercises or 
avoid sedentary life styles and also take such medicines which improve the action of 
insulin. This requires less often blood sugar monitoring, compared to Type 1, but 
requires constant and periodic medical monitoring and supervision. 
       Diabetes is a manageable disease if one knows how to control the sugar levels. 
But uncontrolled diabetes can give rise to so many health complications such as Heart 
Disease, Kidney Disease, Blindness, Brain Failure and Amputations of legs or Limbs. 
Treatment of diabetes mellitus 
Modalities of treatment 
 Diet      
 Physical exercise 
 Insulin 
 Oral anti-diabetic agents 
 
Oral anti-diabetic agents 
 Oral anti-diabetic agents are of use in type-2 Diabetes Mellitus when it is not 
controlled by diet and exercise. These drugs can bring the blood glucose level back to 
normal in mild diseases.  
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Drugs 
Sulfonyl ureas 
First Generation 
 Tolbutamide 
 Chlorpropamide 
 Tolazamide 
 Acetohexamide 
Second Generation 
 Glibenclamide (Glyburide) 
 Glipizide 
 Gliclazide 
 Glimepride 
Biguanides 
 Metformin 
 Phenformin 
Meglitinides 
• Repaglinide 
• Nateglinide 
Thiazolidinediones 
 Pioglitazone 
 Rosiglitazone 
Alpha glucosidase inhibitors 
 Acarbose 
 Miglitol 
Newer drugs 
 Pramlintide 
 Exenatide 
 Sitagliptin 
 Mosapride 
 Diapep 277 
 Vildagliptin 
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Antimicrobial Agents 
The control of pathogens place important role in chemotherapy. The existing 
molecule had been resisted due to mutational changes; this lead to severity of disease 
is increased. In-order to avoid resistance the selection of target protein place 
prominent role in chemotherapeutic agents.  
These are the agents which kill or inhibit the growth of micro-organisms such 
as bacteria, protozoan, fungi & Viruses. It produce both bacteriostatic & bactericidal 
action based on the concentration. 
Drugs: 
There are the two main classes of anti-microbial agents  
1. From natural source 
a. Beta-lactam antibiotics- Penicillin & Cephalosporin   
b. Protease inhibitors 
2. Synthetic agents 
a. Sulphonamides, Cotrimazole, Quinalones 
b. Anti-fungal 
c. Anti-viral 
d. Anti-malarial 
e. Anti-protozoval  
f. Anti-tubercular 
g. Anti-leprotic  
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Literature Review 
 
Enrique Ruiz., et al., (2012) A facile, efficient and environment-friendly 
protocol for the synthesis of 6-chloro-5-formyl-1,4-dihydropyridine derivatives has 
been developed by the convenient ultrasound-mediated reaction of 2(1H)pyridine 
derivatives with the Vilsmeier–Haack reagent. 
N
H
HOOC
CH 3
CHO
Cl
 
Product X 
2a 
2b 
2c 
2d 
H 
-NO2 
3-NO2 
4-NO2 
 
Chunchi Lin and Ching-Fa Yao., et al., (2005) 4-substituted-1,4-
dihydropyridines from the reaction of different aryl or alkyl aldehydes, 1,3-
cyclohexanedione, ethyl acetoacetate and ammonium acetate in the presence of 
catalytic amount of iodine at room temperature. The advantages such as shorter 
reaction times, milder conditions, simplicity of the reaction, excellent product yields. 
Tao Chen, Xiao-Ping Xu., et al., (2011) 1,4-dihydropyridine scaffold, indol-
3-yl-5-oxo-1,4,5,6,7,8- hexahydroquinoline, and indol-3-yl-1,4-dihydropyridine 
derivatives were facilely synthesized through three-component reactions of aromatic 
aldehydes, 3-cyanoacetyl indoles with 3-amino-2-enones in the presence of 
ammonium acetate. The 1,4-dihydropyridine core structure can be efficiently 
aromatized in the presence of stoichiometric 2,3-dichloro-5,6-dicyano-1,4-
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benzoquinone (DDQ). The advantages of the present protocol are atom-economy, 
simple work-up and easy purification of products by non-chromatographic methods. 
N
H
N
H
C H 3
NC
OCH 3
O
R
1
R
2
R 1 =  B r ,  N O
2 ,
 C l
2
,  C H
3
,  O C H
3
R 2 =  C H
3
,  O C H
3
 
Neeloo Singh., et al., (2011) Glycosyl 1,4-dihydropyridine analogue (2,6-
dimethyl-4-(3-O-benzyl-1,2-O-isopropylidene-b-L-threo pentofuranos-4-yl)-1-
phenyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid diethyl ester) synthesized , 
inhibited Leishmania donovani infection in vitro and in hamsters (Mesocricetus 
auratus) when administered orally. This analogue is nontoxic, cell-permeable and 
orally effective. This glycosyl dihydropyridine analogue functioned through arrest of 
cells in sub-G0/G1-phase, triggering mitochondrial membrane depolarization-
mediated programmed cell death of the intracellular amastigotes. 
J. Jasmal Abdul Nasser., et al., (2011), a series of 1,4  DHP derivatives  have 
been prepared by Hantzsch method. The structure of synthesized compounds were 
conformed by FTIR, 1H NMR, 13NMR, Mass spectroscopy & elemental analysis. 
The compounds have been screened for preliminary anticancer activity against 
HepaG2(Liver), Hela (Cervical) & MCF-7 ( Breast) cancer cells. The compounds 2a 
is highly active against   HepaG2, MCF-7 and 3a is highly active against Hela. 
N
H
NH
ORO
NH
NH
NH2
S
CH3CH3
NHS
NH2
2a: R- 4-OH-3-OCH3-Ph
 
N
H
NH
ORO
NH
NH
NH2
O
CH3CH3
NHO
NH2
3a: R- 4-OH-3-OCH
3
-Ph
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Devanand B. Shinde., et al., (2006) A novel method, which is eco friendly, 
cost effective, solvent free, was developed for the synthesis of 1,4dihydropyridines 
from ethyl acetoacetate, aldehyde and ammonium acetate under domestic microwave 
oven. The yield of 1,4DHP enhanced while the reaction time was reduced. 
Roberta Budriesi., et al., (1998) The effect of the dihydropyridine derivative, 
1,4-dihydro-2,6-dimethyl-4- fluorenon-4-yl.pyridine-3,5-dicarboxylic acid diallyl 
ester fluodipine was studied in vitro in different rabbit, rat and guinea pig preparations 
and in vivo in the rabbit in order to characterize its pharmacological profile at cardiac 
and at vascular sites. The highest tissue selectivity was observed in guinea pig 
preparations: fluodipine (B) was about 2–3 times more effective than nifedipine (A) 
on chronotropism and inotropism in isolated atria, and about 150 times less effective 
on aortic strip contraction. 
 
Pierfranco Ioan., et al., (2005) Novel substituted 1,4-dihydropyridines with a 
3-methoxy-flavone moiety were synthesized and structural modifications of the 
substituent’s in the dihydropyridine ring of nifedipine were carried out in order to find 
tissue specific compounds. The negative inotropic, chronotropic and vasorelaxant 
effects were investigated on guinea-pig left, right atria and aortic strips. The different 
residues in the 1,4-dihydropyridine ring could modulate the chronotropic versus 
inotropic activity. 
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1
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2
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2
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Jonna Rzeszowska- wolny., et al., (2005) Compounds of the 1,4-
dihydropyridine (1,4-DHP) series have been shown to reduce spontaneous, alkylation- 
and radiation induced mutation rates in animal test systems. Here we report studies 
using AV-153, the 1,4-DHP derivative that showed the highest antimutagenic activity 
in those tests, to examine if it modulates DNA repair in human peripheral blood 
lymphocytes and in two human lymphoblastoid cell lines, Raji and HL-60. This 
compound’s structure to that of dihydronicotinamide, a substrate for poly(ADP-
rybose)polymerase, the modulation of DNA repair by AV-153 could involve an 
influence on poly(ADP) ribosylation. 
N
H
CH3CH3
COOR
5COOR 3
R
4
AV-153
R
4
- COONa
R
3
=R
5
=OC
2
H
5
 
 Nadezhda I. Ryabokon., et al., (2009) a compound of the carbonyl-1,4-
dihydropyridine series (AV-153 or sodium 3,5-bis-ethoxycarbonyl-2,6-dimethyl-1,4-
dihydropyridine-4-carboxylate), which has high efficiency in stimulating DNA repair, 
can simultaneously modulate apoptosis in human cells. Peripheral blood lymphocytes 
of healthy donors were used in this study. DNA strand-break rejoining was assessed 
with the alkaline comet assay after a 3-h incubation of lymphocytes in the presence of 
                                                                                                             Literature Review 
 
Dept. of Pharmaceutical Chemistry, Madurai Medical College Page 16 
 
a wide range of concentrations of AV-153 (10−10–10−5 M).It reveals that maximal 
efficiency of 67% was found for reduction of DNA strand breaks, while for MN cells 
and apoptotic cells the efficiencies were, respectively, 47% and 44%. 
Antonio Morello., et al.,(2000) A series of 3-chloro-phenyl-1,4-
dihydropyridine derivatives produced different degrees of inhibition of parasite 
growth and respiration on clone Brener, LQ and Tulahuen strains of Trypanosome 
cruzi epimastigotes. Respiratory chain inhibition appears to be a possible determinant 
of the trypanosomicidal activity of this compounds. The presence of a fused ring on 
the dihydropyridine moiety significantly diminished the inhibitory effects. 
N
H
CH3CH3
COOR 5R3COO
Cl
1b  R
3
= CH
3 
; R
5
=C
2
H
5
1a R
3
=R
5
=CH
3
 
Afshin Fassihi., et al.,(2009) A series of 4-substituted imidazolyl-2,6-
dimethyl-N3,N5 bisaryl-1,4-dihydropyridine-3,5-dicarboxamides were prepared. 
They were screened as anti-tubercular agents against Mycobacterium tuberculosis 
H37Rv. Minimum inhibitory concentrations (MICs) were determined using agar 
proportion method. Compound 3i with 1-benzyl-2-methylthio-1H-imidazole-5-yl 
substituent at C-4 position and 40-chloromophenyl group at C-3 and C-5 positions of 
the 1,4-dihydropyridine ring was the most potent one among the tested compounds. It 
was as potent as rifampicin against M. tuberculosis H37RV. Compound 3l also was 
an active anti-tubercular agent with the same substituent as compound 3i at the C-4 
position and 30-pyridyl group at C-3 and C-5 positions of the 1,4-dihydropyridine 
ring. 
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N
H
CH3
N
N
CH3
NH
Ar
-
O
NH
Ar
-
O
S CH3
3i: Ar=4-Cl- Pheneyl, 3j: Ar= 3 Pyridyl
 
Takashi Adachi., et al.,(1997) (4R)-(-)-2-(Nicotinoylamino)ethyl3-
nitrooxypropyl 2,6-dimethyl-4-(3_nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate 
, a new calcium antagonist, was synthesized via both enantioselective hydrolysis and 
transesterification of prochiral bis[2-(nicotinoylamino)ethyl]ester 2HCl by using 
enzymes. Enzymatic transesterification of 5 with 3-nitrooxypropanol gave 1 in more 
than 99.5% directly. 
N
N
H
CH3CH3
O
CH2
O
O
O
ONO 2
NO 2
NH
O
 
Zanna Hyvonen., et al., (2002) Double-charged 1,4-dihydropyridine (1,4-DHP) 
amphiphiles have been shown to condense DNA and efficiently transfect it into cells 
invitro. In this study examined  how those chemical modifications of amphiphile–
DNA complexes (amphiplexes) affect their interactions with extracellular polyanions 
(glycosaminoglycans, albumin) and lipid bilayers, their cellular uptake and 
intracellular distribution. To evaluate cellular uptake, CV1-P cells were incubated 
with labeled DNA–amphiphile complexes and analyzed by flow cytometry. The 
results showed that biophysical properties of compounds can be changed by slight 
structural modifications. 
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N
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N
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R1   R3=R5                          Compound 
 H   C10H21     I 
 H   C
12
H
25
     II 
 H   C
14
H
29
     III 
 H   C
16
H
33
     IV 
 CH3   C
12
H
25
     V 
 
Antonio Morello., et al., (1997) A series of nitro aryl 1,4-dihydropyridine 
derivatives produced inhibition of both cell growth and oxygen consumption on 
Tulahuen and LQ strains, and clone Dm 28c of epimastigotes of Trypanosoma cruzi. 
Nicardipine was found to be the most potent derivative in both growth cell (I50 5 70 
mM) and oxygen uptake (I50 5 26 mM in intact parasites, I50 5 325 mM in situ 
mitochondria). Thus, nicardipine, the most potent derivative, exhibited the highest 
apparent rate constant, ku, (0.043 min21). On the other hand, no susceptibility 
differences by strains and clone Dm 28c to the action of these drugs were found. 
N
H
CH3CH3
COOR 3R 4 OOC
R 1
R 2
 
1, 4 DHPs   R1  R2  R3              R4 
Nifidepine  -NO2  -H  -CH3  -CH3 
Nitrandepine  -H  -NO2  -CH3  -CH2 – CH3  
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Jose Marco-Contelles., et al.,(2004) Synthesis, electrochemical and biological 
studies on polyfunctionalized 4 ferrocenyl -4H-pyran and 4-ferrocenyl- 1,4 dihydropyridine 
derivatives. The first synthesis of polyfunctionalized 4-ferrocenyl-4H-pyran and 4-ferrocenyl-
1,4-dihydropyridine derivatives, as well as some of their relevant properties, including an 
electrochemical study and some aspects of their biological profile have been described. 
N
H
CH3CH3
OC 2H5
OCH3
H5C2O
Fe
2+
 
 Ameen A. Abu-Hashem b,c., et al.,(2007) Synthesis and anti-microbial activity of 
some 1- substituted amino-4,6-dimethyl-2-oxo-pyridine-3-carbonitrile derivatives.The 
antibacterial and antifungal activities of the synthesized compounds were evaluated. The 
obtained data indicated that the majority of the tested compounds exhibited both antibacterial 
and antifungal activities, comparable effect to a well known antibacterial and antifungal 
agent. 
N
NH
CH3
CH3 O
CN
NH
N
O
CH3
CN
CH3
                          
N
N
O
O
CH3
CH3
CN
O
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N
OCH3
CH3
CH3
NH NH
O
O
O
 
JC Cherrnannz, JL Krausl., et al., Synthesis and antiviral activity of N-4’-
dihydropyridinyl and dihydroquinolinylcarbonyl- 2-hydroxymethyl-5-[cytosin-l’-yl]-1,3-
oxathiolane derivatives against human immunodeficiency virus and duck hepatitis B virus.  
S
N
N
O
R
O
O
N
CH3
N
CH3
CH3
N
+
CH3
CH3
R=A
R=B
R=C
 
JAM Christiaans., et al., (1994) Synthesis and in vitro pharmacology of a 
series of hybrid molecules possessing 1,4-dihydropyridine calcium-channel blocking 
activity and histamine H,-agonistic properties. 
 
N
H
EtOOC
CH3
COOEt
S
NH NH NH
N
NH
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Marija Bester-Rogac., et al., Molecular interactions of 1,4-dihydropyridine 
derivatives with selected organic solvents: A volumetric, spectroscopic and 
computational study. 
N
H
CH3 CH3
O
R 2
OO
O
R 1
N
H
CH3 CH3
O
O
OCH3
NH2
X X
S
OO
-
O
 
Compound  R1   R2   X         
     Nifidipine  CH3   CH3   2NO2 
     Nitredipine  CH3   CH3   3NO2 
     Nimodepine  C2H4OCH3  CH(CH3)2  3NO2 
. Alkefl and A.G. Swanson, (1990) formation, synthetic utility and structure 
elucidation of a 2-bromomethyl 1,4-dihydropyridine 
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              M. Wojewodzka., et al., Dihydropyridines decrease X-ray-induced DNA 
base damage in mammalian cells.  
N
H
COONa
CH3 CH3
OO
OCH3 O
CH3
H
 
             Neven Zarkovic., et al., (2006) Bioactive 1,4-dihydroisonicotinic acid 
derivatives prevent oxidative damage of liver cells. 
 
N
H
COR
CH3 CH3
O
O
H
5
C
2
O
O
C
2
H
5
H
1a, R=ONa
1b, R= HNCH(CooNa) CH2 -CH2
1c, R=HNCH2 - CH2 - SO3Na
 
Vanga Malla Reddy., et al., (2011) Molecular docking studies and in vitro screening 
of new dihydropyridine derivatives as human MRP1 inhibitors.  
N
H
CH 3 C H 3
O
N H N H
O
XX
R
R
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

            Yuji Takahataa., et al.,  (1997) A comparative study of principal component 
and linear multiple regression analysis in SAR and QSAR applied to 1,4-
dihydropyridine calcium channel antagonists (nifedipine analogues) 
 
             Yuichi Hattori., et  al., Invitro assessment for vascular selectivity of a new 
dihydro pyridine  derivatives.        
  


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Aim and Objective of the Work 
  
 The chemistry and pharmacology of new serious of 1, 4 DHP derivatives have 
been great interest, because of various biological action. 
 In search for new bioactive molecule, it was thought worthwhile to incorporate 
some additional semicarbazide & thio-semicarbazide moiety in the 1,4 DHP nucleolus 
and study their biological activity, the review of literature reveal prompted us to 
synthesis  of substituted 1, 4 DHP derivatives with  semicarbazide & 
thiosemicarbazide side chain and those will screened for anti-diabetic & anti-
microbial action. 
 
  
 
 
 
 
 
 
 
 
  Plan of Work 
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Plan of work 
 
 To design the molecule with help of software tools. 
 To establish the methods of synthesis for the proposed compounds. 
 To carry out the preliminary test such as physical constant determination, 
solubility….etc. 
 To confirm the structure of the synthesized compounds by using FTIR,
 1 
H 
NMR, Mass spectra. 
 To evaluate the proposed compounds for their antimicrobial, anti-.diabetic 
action. 
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Scheme 
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Table – 1 
Different substitution in compounds  
Compound 
No. 
Structure R 
 
A1 
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H
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R
NH
NH
O
NH2
S
NH
NH
NH2
S
O
 
 
CH3CHO 
 
B1 
 
CHO
 
 
C1 
 
OH CHO
 
 
D1 
 
CH3 CHO
 
 
E1 O
CH3
CHO
 
 
A2 
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CH3 CHO
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Experimental work 
Table-2 
List of Software used 
Name of the software Version URL Link 
Acetelion Property Exlorer 2001 www.oranicwebportal.com 
Molinspiration On-line www.molinspiration.com 
Graph pad prisam 3.05 - 
 
Table-3 
List of Chemicals/ Reagents used 
S. No Name of the Chemical/ Reagent Manufacturer 
1 Ethylacetoacetate Sigma aldrich 
2 Ammonium acetate Spectrochem 
3 Formaldehyde Sigma aldrich 
4 Benzaldehyde Fisher scientific 
5 P- OH Benzaldehyde Sigma aldrich 
6 P- CH3 Benzaldehyde Sigma aldrich 
7 P- OCH3 Benzaldehyde Sigma aldrich 
8 DMSO Spectrochem 
9 Ethanol Qualigens 
10 Ethyl acetate Fisher scientific 
11 Chloroform Sigma aldrich 
12 Glacial Acetic Acid Sigma aldrich 
13 Isopropyl alcohol Fisher scientific 
14 Xylinol  Fisher scientific 
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Table-4 
List of Equipments used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. No Instrument Manufactures 
1 Digital electronic balance Shimadzu Ax - 200 
2 Magnetic stirrer Remi Equipments, Chennai 
3 Melting point apparatus Sunbim, Guna Enterprises 
4 FT-IR Spectroscopy Perkin Elmer-I 
5 
1
H-NMR Spectroscopy Bruker – NMR 400 MHz 
6 Mass Spectroscopy JEOL GC mate 
7 Hot air oven Picses 
8 Microwave oven ONIDA electronics 
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Figure-1; Molecular design by using Osiris’s property explorer 
Compound-A1 
 
Compound-B1 
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Compound-C1 
 
Compound-D1 
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Compound-E1 
 
Compound-A2 
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Compound-B2 
 
Compound-C2 
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Compound-D2 
 
Compound-E2 
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Mol-inspiration 
 Virtual screening or in silico screening is the use of computational chemistry 
techniques to analyze large chemical databases in order to identify possible new drug 
candidates. Virtual screening techniques range from simple ones, based on the 
presence or absence of specific substructures, or match in calculated molecular 
properties, up to sophisticated virtual docking methods aimed at fitting putative ligand 
molecules into the target receptor site.  
Miscreen - a Molinspiration virtual screening engine offers very good balance 
between screening speed, requirements on information needed to start a new virtual 
screening project and screening performance.  
 The miscreen engine first analysis a training set of active structures (in 
extreme case even single active molecule is sufficient to built a usable model) and 
compares it with inactive molecules by using sophisticated Bayesian statistics. Only 
SMILES or SDfile structures of active molecules are sufficient for the training, no 
information about the active site or binding mode is necessary. This is particularly 
useful in projects where structure-based approach cannot be applied because 
information about 3D receptor structure is not available, for example in screens 
aiming to find ligands modulating G-protein coupled receptors. Based on this analysis 
a fragment-based model is developed, where for each substructure fragment a 
bioactivity contribution is calculated. Once a model is build the bioactivity of 
screened molecules may be then calculated as a sum of activity contributions of 
fragments in these molecules. This provides a molecule activity score (a number, 
typically between -3 and 3). Molecules with the highest activity score have the highest 
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probability to be active. Such in silico screening is very fast, large collections of 
molecules (more than 100'000 molecules) may be screened in an hour.  
Molecular property 
LogP (octanol/water partition coefficient)  
LogP is calculated by the methodology developed by Mol-inspiration as a sum of 
fragment-based contributions and correction factors. Method is very robust and is able 
to process practically all organic, and most organometallic molecules. 
Molecular Polar Surface Area TPSA  
 It is calculated based on the methodology  as a sum of fragment contributions. 
O- and N- centered polar fragments are considered. PSA has been shown to be a very 
good descriptor characterizing drug absorption, including intestinal absorption, 
bioavailability, Caco-2 permeability and blood-brain barrier penetration.  
Molecular Volume  
Method for calculation of molecule volume developed at Mol-inspiration is based on 
group contributions. These have been obtained by fitting sum of fragment 
contributions to "real" 3D volume for a training set of about twelve thousand, mostly 
drug-like molecules. 3D molecular geometries for a training set were fully optimized 
by the semi-empirical AM1 method.  
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"Rule of 5" Properties  
 It is set of simple molecular descriptors used by Lipinski in formulating his 
"Rule of 5" . The rule states, that most "drug-like" molecules have log P <= 5, 
molecular weight <= 500, number of hydrogen bond acceptors <= 10, and number of 
hydrogen bond donors <= 5. Molecules violating more than one of these rules may 
have problems with bioavailability. The rule is called "Rule of 5",  
Number of Rotatable Bonds – nrotb  
 This simple topological parameter is a measure of molecular flexibility. It has 
been shown to be a very good descriptor of oral bioavailability of drugs. Rotatable 
bond is defined as any single non-ring bond, bounded to non terminal heavy (i.e., non-
hydrogen) atom. Amide C-N bonds are not considered because of their high rotational 
energy barrier.  
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Figure-2: Compound A1 
 
miSMILES CC1C(C(=O)NNC(N)=S)=C(C)NC(C)=C1C(=O)NNC(N)=S 
Properties 
miLogP         -0.047 
TPSA           146.323 
natoms         23.0 
MW             357.465 
nON            9 
nOHNH          9 
nviolations    1 
nrotb          6 
volume                 301.417 
 
Bioactivity score 
GPCR ligand                -0.63 
Ion channel modulator      -0.62 
Kinase inhibitor           -0.86 
Nuclear receptor ligand    -0.90 
Protease inhibitor         -0.37 
Enzyme inhibitor           -0.51 
 
 
Molecular Formula  = C12H19N7O2S2 
Formula Weight  = 357.45496 
Composition   = C (40.32%) H (5.36%) N (27.43%) O (8.95%) S (17.94%) 
Molar Refractivity  = 94.16 ± 0.3 cm
3 
Molar Volume   = 256.1 ± 3.0 cm
3 
Parachor   = 743.7 ± 6.0 cm
3 
Index of Refraction  = 1.656 ± 0.02 
Surface Tension  = 71.1 ± 3.0 dyne/cm 
Density   = 1.395 ± 0.06 g/cm
3 
Dielectric Constant  = Not available 
Polarizability   = 37.32 ± 0.5 10
-24
cm
3 
Monoisotopic Mass  = 357.104163 Da 
Nominal Mass   = 357 Da 
Average Mass   = 357.455 Da 
M+    = 357.103614 Da 
M-    = 357.104711 Da 
[M+H]+   = 358.111439 Da 
[M+H]-    = 358.112537 Da 
[M-H]+    = 356.095789 Da 
[M-H]-    = 356.096886 Da 
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                                                                  Compound B1 
 
miSMILES CC2=C(C(=O)NNC(N)=S)C(c1ccccc1)C(C(=O)NNC(N)=S)=C(C)N2 
Properties 
miLogP         1.275 
TPSA           146.323 
natoms         28.0 
MW             419.536 
nON            9 
nOHNH          9 
nviolations    1 
nrotb          7 
volume         356.264 
 
Bio activity score 
GPCR ligand                -0.59 
Ion channel modulator      -0.54 
Kinase inhibitor           -0.81 
Nuclear receptor ligand    -0.81 
Protease inhibitor         -0.56 
Enzyme inhibitor           -0.47 
 
 
Molecular Formula  = C17H21N7O2S2 
Formula Weight  = 419.52434 
Composition   = C(48.67%) H(5.05%) N(23.37%) O(7.63%) S(15.29%) 
Molar Refractivity  = 113.89 ± 0.3 cm
3 
Molar Volume   = 300.3 ± 3.0 cm
3 
Parachor   = 877.5 ± 6.0 cm
3 
Index of Refraction  = 1.683 ± 0.02 
Surface Tension  = 72.9 ± 3.0 dyne/cm 
Density   = 1.396 ± 0.06 g/cm
3 
Dielectric Constant  = Not available 
Polarizability   = 45.15 ± 0.5 10
-24
cm
3 
Monoisotopic Mass  = 419.119813 Da 
Nominal Mass   = 419 Da 
Average Mass   = 419.5243 Da 
M+    = 419.119264 Da 
M-    = 419.120362 Da 
[M+H]+   = 420.127089 Da 
[M+H]-    = 420.128187 Da 
[M-H]+    = 418.111439 Da 
[M-H]-    = 418.112537 Da 
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Compound C1 
 
miSMILES CC2=C(C(=O)NNC(N)=S)C(c1ccc(O)cc1)C(C(=O)NNC(N)=S)=C(C)N2 
Properties 
miLogP         0.796 
TPSA           166.551 
natoms         29.0 
MW             435.535 
nON            10 
nOHNH          10 
nviolations    1 
nrotb          7 
volume         364.282 
 
Bio activity score 
GPCR ligand                -0.59 
Ion channel modulator      -0.54 
Kinase inhibitor           -0.81 
Nuclear receptor ligand    -0.81 
Protease inhibitor         -0.56 
Enzyme inhibitor           -0.47 
 
Molecular Formula  = C17H21N7O3S2 
Formula Weight  = 435.52374 
Composition   =  C(46.88%) H(4.86%) N(22.51%) O(11.02%) S(14.72%) 
Molar Refractivity  = 115.77 ± 0.3 cm
3 
Molar Volume   = 298.7 ± 3.0 cm
3 
Parachor   = 892.7 ± 6.0 cm
3 
Index of Refraction  = 1.702 ± 0.02 
Surface Tension  = 79.7 ± 3.0 dyne/cm 
Density   = 1.457 ± 0.06 g/cm
3 
Dielectric Constant  = Not available 
Polarizability   = 45.89 ± 0.5 10
-24
cm
3 
Monoisotopic Mass  = 435.114728 Da 
Nominal Mass   = 435 Da 
Average Mass   = 435.5237 Da 
M+    = 435.114179 Da 
M-    = 435.115276 Da 
[M+H]+   = 436.122004 Da 
[M+H]-    = 436.123101 Da 
[M-H]+    = 434.106354 Da 
[M-H]-    = 434.107451 Da 
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Compound D1 
 
miSMILES CC2=C(C(=O)NNC(N)=S)C(c1ccc(C)cc1)C(C(=O)NNC(N)=S)=C(C)N2 
Properties 
miLogP         1.723 
TPSA           146.323 
natoms         29.0 
MW             433.563 
nON            9 
nOHNH          9 
nviolations    1 
nrotb          7 
volume         372.825 
 
Bio activity score 
GPCR ligand                -0.60 
Ion channel modulator      -0.58 
Kinase inhibitor           -0.81 
Nuclear receptor ligand    -0.81 
Protease inhibitor         -0.60 
Enzyme inhibitor           -0.50 
 
Molecular Formula  = C18H23N7O2S2 
Formula Weight  = 433.55092 
Composition   =  C(49.87%) H(5.35%) N(22.61%) O(7.38%) S(14.79%) 
Molar Refractivity  = 118.72 ± 0.3 cm
3 
Molar Volume   = 316.5 ± 3.0 cm
3 
Parachor   = 915.8 ± 6.0 cm
3 
Index of Refraction  = 1.673 ± 0.02 
Surface Tension  = 70.0 ± 3.0 dyne/cm 
Density   = 1.369 ± 0.06 g/cm
3 
Dielectric Constant  = Not available 
Polarizability   = 47.06 ± 0.5 10
-24
cm
3 
Monoisotopic Mass  = 433.135463 Da 
Nominal Mass   = 433 Da 
Average Mass   = 433.5509 Da 
M+    = 433.134914 Da 
M-    = 433.136012 Da 
[M+H]+   = 434.142739 Da 
[M+H]-    = 434.143837 Da 
[M-H]+    = 432.127089 Da 
[M-H]-    = 432.128187 Da 
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Compound E1 
 
miSMILES COc2ccc(C1C(C(=O)NNC(N)=S)=C(C)NC(C)=C1C(=O)NNC(N)=S)cc2 
Properties 
miLogP         1.331 
TPSA           155.557 
natoms         30.0 
MW             449.562 
nON            10 
nOHNH          9 
nviolations    1 
nrotb          8 
volume         381.81 
 
Bio activity score 
GPCR ligand                -0.59 
Ion channel modulator      -0.57 
Kinase inhibitor           -0.79 
Nuclear receptor ligand    -0.77 
Protease inhibitor         -0.58 
Enzyme inhibitor           -0.48 
Molecular Formula  = C18H23N7O3S2 
Formula Weight  = 449.55032 
Composition   = C(48.09%) H(5.16%) N(21.81%) O(10.68%) S(14.27%) 
Molar Refractivity  = 120.57 ± 0.3 cm
3 
Molar Volume   = 324.3 ± 3.0 cm
3 
Parachor   = 936.1 ± 6.0 cm
3 
Index of Refraction  = 1.665 ± 0.02 
Surface Tension  = 69.4 ± 3.0 dyne/cm 
Density   = 1.386 ± 0.06 g/cm
3 
Dielectric Constant  = Not available 
Polarizability   = 47.80 ± 0.5 10
-24
cm
3 
Monoisotopic Mass  = 449.130378 Da 
Nominal Mass   = 449 Da 
Average Mass   = 449.5503 Da 
M+    = 449.129829 Da 
M-    = 449.130926 Da 
[M+H]+   = 450.137654 Da 
[M+H]-    = 450.138751 Da 
[M-H]+    = 448.122004 Da 
[M-H]-    = 448.123101 Da 
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Compound A2 
 
miSMILES CC1C(C(=O)NNC(N)=O)=C(C)NC(C)=C1C(=O)NNC(N)=O 
Properties 
miLogP         -1.129 
TPSA           180.465 
natoms         23.0 
MW             325.329 
nON            11 
nOHNH          9 
nviolations    2 
nrotb          4 
volume         283.661 
 
Bio activity score 
GPCR ligand                -0.22 
Ion channel modulator      -0.34 
Kinase inhibitor           -0.49 
Nuclear receptor ligand    -0.71 
Protease inhibitor         -0.23 
Enzyme inhibitor           -0.37 
 
Molecular Formula  = C12H19N7O4 
Formula Weight  = 325.32376 
Composition   = C(44.30%) H(5.89%) N(30.14%) O(19.67%) 
Molar Refractivity  = 79.64 ± 0.3 cm
3 
Molar Volume   = 240.3 ± 3.0 cm
3 
Parachor   = 660.8 ± 6.0 cm
3 
Index of Refraction  = 1.576 ± 0.02 
Surface Tension  = 57.1 ± 3.0 dyne/cm 
Density   = 1.353 ± 0.06 g/cm
3 
Dielectric Constant  = Not available 
Polarizability   = 31.57 ± 0.5 10
-24
cm
3 
Monoisotopic Mass  = 325.149852 Da 
Nominal Mass   = 325 Da 
Average Mass   = 325.3238 Da 
M+    = 325.149304 Da 
M-    = 325.150401 Da 
[M+H]+   = 326.157129 Da 
[M+H]-    = 326.158226 Da 
[M-H]+    = 324.141478 Da 
[M-H]-    = 324.142576 Da 
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Compound B2 
 
miSMILES CC2=C(C(=O)NNC(N)=O)C(c1ccccc1)C(C(=O)NNC(N)=O)=C(C)N2 
Properties 
miLogP         0.193 
TPSA           180.465 
natoms         28.0 
MW             387.4 
nON            11 
nOHNH          9 
nviolations    2 
nrotb          5 
volume         338.508 
 
Bio activity score 
GPCR ligand                -0.25 
Ion channel modulator      -0.31 
Kinase inhibitor           -0.50 
Nuclear receptor ligand    -0.65 
Protease inhibitor         -0.45 
Enzyme inhibitor           -0.35 
Molecular Formula  = C17H21N7O4 
Formula Weight  = 387.39314 
Composition   = C(52.71%) H(5.46%) N(25.31%) O(16.52%) 
Molar Refractivity  = 99.37 ± 0.3 cm
3 
Molar Volume   = 284.5 ± 3.0 cm
3 
Parachor   = 794.6 ± 6.0 cm
3 
Index of Refraction  = 1.615 ± 0.02 
Surface Tension  = 60.7 ± 3.0 dyne/cm 
Density   = 1.361 ± 0.06 g/cm
3 
Dielectric Constant  = Not available 
Polarizability   = 39.39 ± 0.5 10
-24
cm
3 
Monoisotopic Mass  = 387.165502 Da 
Nominal Mass   = 387 Da 
Average Mass   = 387.3931 Da 
M+    = 387.164954 Da 
M-    = 387.166051 Da 
[M+H]+   = 388.172779 Da 
[M+H]-    = 388.173876 Da 
[M-H]+    = 386.157129 Da 
[M-H]-    = 386.158226 Da 
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Compound C2 
 
miSMILES CC2=C(C(=O)NNC(N)=O)C(c1ccc(O)cc1)C(C(=O)NNC(N)=O)=C(C)N2 
Properties 
miLogP         -0.286 
TPSA           200.693 
natoms         29.0 
MW             403.399 
nON            12 
nOHNH          10 
nviolations    2 
nrotb          5 
volume         346.526 
 
Bio activity score 
GPCR ligand                -0.21 
Ion channel modulator      -0.26 
Kinase inhibitor           -0.45 
Nuclear receptor ligand    -0.51 
Protease inhibitor         -0.43 
Enzyme inhibitor           -0.30 
Molecular Formula  = C17H21N7O5 
Formula Weight  = 403.39254 
Composition   = C(50.62%) H(5.25%) N(24.31%) O(19.83%) 
Molar Refractivity  = 101.26 ± 0.3 cm
3 
Molar Volume   = 282.9 ± 3.0 cm
3 
Parachor   = 809.8 ± 6.0 cm
3 
Index of Refraction  = 1.634 ± 0.02 
Surface Tension  = 67.0 ± 3.0 dyne/cm 
Density   = 1.425 ± 0.06 g/cm
3 
Dielectric Constant  = Not available 
Polarizability   = 40.14 ± 0.5 10
-24
cm
3 
Monoisotopic Mass  = 403.160417 Da 
Nominal Mass   = 403 Da 
Average Mass   = 403.3925 Da 
M+    = 403.159868 Da 
M-    = 403.160965 Da 
[M+H]+   = 404.167693 Da 
[M+H]-    = 404.16879 Da 
[M-H]+    = 402.152043 Da 
[M-H]-    = 402.15314 Da 
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Compound D2 
 
miSMILES CC2=C(C(=O)NNC(N)=O)C(c1ccc(C)cc1)C(C(=O)NNC(N)=O)=C(C)N2 
Properties 
miLogP         0.642 
TPSA           180.465 
natoms         29.0 
MW             401.427 
nON            11 
nOHNH          9 
nviolations    2 
nrotb          5 
volume         355.069 
 
Bio activity score 
GPCR ligand                -0.28 
Ion channel modulator      -0.36 
Kinase inhibitor           -0.52 
Nuclear receptor ligand    -0.65 
Protease inhibitor         -0.49 
Enzyme inhibitor           -0.39 
 
Molecular Formula  = C18H23N7O4 
Formula Weight  = 401.41972 
Composition   = C(53.86%) H(5.78%) N(24.43%) O(15.94%) 
Molar Refractivity  = 104.20 ± 0.3 cm
3 
Molar Volume   = 300.8 ± 3.0 cm
3 
Parachor   = 832.8 ± 6.0 cm
3 
Index of Refraction  = 1.609 ± 0.02 
Surface Tension  = 58.7 ± 3.0 dyne/cm 
Density   = 1.334 ± 0.06 g/cm
3 
Dielectric Constant  = Not available 
Polarizability   = 41.30 ± 0.5 10
-24
cm
3 
Monoisotopic Mass  = 401.181152 Da 
Nominal Mass   = 401 Da 
Average Mass   = 401.4197 Da 
M+    = 401.180604 Da 
M-    = 401.181701 Da 
[M+H]+   = 402.188429 Da 
[M+H]-    = 402.189526 Da 
[M-H]+    = 400.172779 Da 
[M-H]-    = 400.173876 Da 
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Compound E2 
 
miSMILES COc2ccc(C1C(C(=O)NNC(N)=O)=C(C)NC(C)=C1C(=O)NNC(N)=O)cc2 
Properties 
miLogP         0.25 
TPSA           189.699 
natoms         30.0 
MW             417.426 
nON            12 
nOHNH          9 
nviolations    2 
nrotb          6 
volume         364.054 
 
Bio activity score 
GPCR ligand                -0.27 
Ion channel modulator      -0.35 
Kinase inhibitor           -0.50 
Nuclear receptor ligand    -0.62 
Protease inhibitor         -0.47 
Enzyme inhibitor           -0.37 
Molecular Formula  = C18H23N7O5 
Formula Weight  = 417.41912 
Composition   = C(51.79%) H(5.55%) N(23.49%) O(19.16%) 
Molar Refractivity  = 106.05 ± 0.3 cm
3 
Molar Volume   = 308.5 ± 3.0 cm
3 
Parachor   = 853.2 ± 6.0 cm
3 
Index of Refraction  = 1.603 ± 0.02 
Surface Tension  = 58.4 ± 3.0 dyne/cm 
Density   = 1.352 ± 0.06 g/cm
3 
Dielectric Constant  = Not available 
Polarizability   = 42.04 ± 0.5 10
-24
cm
3 
Monoisotopic Mass  = 417.176067 Da 
Nominal Mass   = 417 Da 
Average Mass   = 417.4191 Da 
M+    = 417.175518 Da 
M-    = 417.176615 Da 
[M+H]+   = 418.183343 Da 
[M+H]-    = 418.184441 Da 
[M-H]+    = 416.167693 Da 
[M-H]-    = 416.16879 Da 
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Molecular synthesis 
Synthesis of Compound A 
CH3
EtO
O
O
+
CH3
OEt
O
O
NH
4
OAc
Ammonium acetate
Reflux up to 2 Hrs
N
H
CH3CH3
OEt
O
EtO
O
CH3
Compound A
CHO
CH3
Acetaldehyde
Ethylacetoacetate  
 
Chemicals Required 
Ethylacetoacetate -0.2 mole 
Ammonium acetate -0.1 mole 
Acetaldehyde  -0.1 mole 
 
Procedure 
 A reaction mixture was made up of ethylacetoacetate (0.2 mol), Ammonium 
acetate( 0.1 mol) acetaldehyde(0.1 mol) in ethanol. It was then heated refluxed for 2 
hr. The obtained solid was filter off, and washed with water and purified by 
recrystalisation from absolute ethanol.  
 
Synthesis of Compound A1 
Compound A
DMSO, Ethanol &  ∆  10  hrs
NH2 NH NH2
S
Compound A 1
N
H
CH3 CH3
NH
O
NH
OCH3
NH
NH2
S
NHS
NH2
N
H
CH3CH3
OEt
O
EtO
O
CH3
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Chemicals Required 
Compound A  - 0.1 mole 
Thiosemicarbazide - 0.1 mole 
DMSO   - 5 ml 
Ethanol  - 10ml 
 
Procedure 
Equal molar weight of compound A and thiosemicarbazide dissolved in ethanol then 
add 5 ml of DMSO. It was the heated under reflux for 10 hr. The solid was obtained, 
after cool and pour it into crushed ice. The solid was collected by filtration, washed 
with water and purified by re-crystallization with ethanol.  
 
Synthesis of Compound A2 
Compound A
DMSO, Ethanol &  ∆  10  hrs
NH2 NH NH2
O
Compound A 2
N
H
CH3CH3
OEt
O
EtO
O
CH
3
N
H
CH3 CH3
NH
O
NH
OCH3
NH
NH2
O
NHO
NH2
 
 
Chemicals Required 
Compound A  - 0.1 mole 
Semicarbazide  - 0.1 mole 
DMSO   - 5 ml 
Ethanol  - 10ml 
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Procedure 
 Equal molar weight of compound A and semicarbazide dissolved in ethanol 
then add 5 ml of DMSO. It was the heated under reflux for 10 hr. The solid was 
obtained, after cool and pour it into crushed ice. The solid was collected by filtration, 
washed with water and purified by re-crystallization with ethanol.  
 
Synthesis of Compound B 
CH3
EtO
O
O
+
CH3
OEt
O
O
NH
4
OAc
Ethyl acetoacetate Ammonium acetate
Reflux up to 2 Hrs
N
H
CH3CH3
OEt
O
EtO
O
Compound B
CHO
Benzaldehyde
 
 
Chemicals Required 
Ethylacetoacetate -0.2 mole 
Ammonium acetate -0.1 mole 
Benzaldehyde  -0.1 mole 
 
 
Procedure 
 A reaction mixture was made up of ethylacetoacetate (0.2 mol), Ammonium 
acetate( 0.1 mol) benzaldehyde (0.1 mol) in ethanol. It was then heated refluxed for 2 
hr. The obtained solid was filter off, and washed with water and purified by 
recrystalisation from absolute ethanol.  
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Synthesis of Compound B1 
 
Compound B
DMSO, Ethanol &  ∆  10  hrs
NH2 NH NH2
S
Compound B 1
N
H
CH3 CH3
NH
O
NH
O
NH
NH2
S
NHS
NH2
N
H
CH
3
CH
3
OEt
O
EtO
O
 
Chemicals Required 
Compound B  - 0.1 mole 
Thiosemicarbazide - 0.1 mole 
DMSO   - 5 ml 
Ethanol  - 10ml 
 
Procedure 
Equal molar weight of compound A and thiosemicarbaside dissolved in ethanol then 
add 5 ml of DMSO. It was the heated under reflux for 10 hr. The solid was obtained, 
after cool and pour it into crushed ice. The solid was collected by filtration, washed 
with water and purified by re-crystallization with ethanol.  
 
Synthesis of Compound B2 
Compound B
DMSO, Ethanol &  ∆  10  hrs
NH2 NH NH2
O
Compound B 2
N
H
CH
3
CH
3
OEt
O
EtO
O
N
H
CH3 CH3
NH
O
NH
O
NH
NH2
O
NHO
NH2
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Chemicals Required 
Compound B  - 0.1 mole 
Semicarbazide  - 0.1 mole 
DMSO   - 5 ml 
Ethanol  - 10ml 
Procedure  
Equal molar weight of compound B and semicarbazide dissolved in ethanol then add 
5 ml of DMSO. It was the heated under reflux for 10 hr. The solid was obtained, after 
cool and pour it into crushed ice. The solid was collected by filtration, washed with 
water and purified by re-crystallization with ethanol.  
Synthesis of Compound C 
CH3
EtO
O
O
+
CH3
OEt
O
O
NH
4
OAc
Ethyl acetoacetate Ammonium acetate
Reflux up to 2 Hrs
N
H
CH3CH3
OEt
O
EtO
O
OH
Compound C
CHO
OH
P - Hydroxy Benzaldehyde
+
 
 
Chemicals Required 
Ethylacetoacetate   -0.2 mole 
Ammonium acetate   -0.1 mole 
Para- Hydroxy Benzaldehyde  -0.1 mole 
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Procedure 
A reaction mixture was made up of ethylacetoacetate (0.2 mol), Ammonium acetate( 
0.1 mol) Para hydroxyl benzaldehyde (0.1 mol) in ethanol. It was then heated refluxed 
for 2 hr. The obtained solid was filter off, and washed with water and purified by 
recrystalisation from absolute ethanol.  
 
Synthesis of Compound C1 
Compound C
DMSO, Ethanol &  ∆  10  hrs
NH2 NH NH2
S
Compound C 1
N
H
CH3 CH3
NH
O
NH
O
NH
NH2
S
NHS
NH2
OH
N
H
CH
3
CH
3
OEt
O
EtO
O
OH
 
Chemicals Required 
Compound C  - 0.1 mole 
Thiosemicarbazide - 0.1 mole 
DMSO   - 5 ml 
Ethanol  - 10ml 
 
Procedure 
Equal molar weight of compound C and thiosemicarbaside dissolved in ethanol then 
add 5 ml of DMSO. It was the heated under reflux for 10 hr. The solid was obtained, 
after cool and pour it into crushed ice. The solid was collected by filtration, washed 
with water and purified by re-crystallization with ethanol.  
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Synthesis of Compound C2 
Compound C
DMSO, Ethanol &  ∆  10  hrs
NH2 NH NH2
O
Compound C 2
N
H
CH
3
CH
3
OEt
O
EtO
O
OH
N
H
CH3 CH3
NH
O
NH
O
NH
NH2
O
NHO
NH2
OH
 
Chemicals Required 
Compound C  - 0.1 mole 
Semicarbazide  - 0.1 mole 
DMSO   - 5 ml 
Ethanol  - 10ml 
 
Procedure 
Equal molar weight of compound C and semicarbazide dissolved in ethanol then add 
5 ml of DMSO. It was the heated under reflux for 10 hr. The solid was obtained, after 
cool and pour it into crushed ice. The solid was collected by filtration, washed with 
water and purified by re-crystallization with ethanol.  
 
Synthesis of Compound D 
CH3
EtO
O
O
+
CH3
OEt
O
O
NH 4OAc
Ethyl acetoacetate Ammonium acetate
Reflux up to 2 Hrs
N
H
CH3CH3
OEt
O
EtO
O
CH3
Compound D
CHO
CH3
P - Methyl Benzaldehyde
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Chemicals Required 
Ethylacetoacetate   -0.2 mole 
Ammonium acetate   -0.1 mole 
Para- Methyl Benzaldehyde   -0.1 mole 
 
Procedure 
 A reaction mixture was made up of ethylacetoacetate (0.2 mol), Ammonium 
acetate( 0.1 mol) paramethyl benzaldehyde (0.1 mol) in ethanol. It was then heated 
refluxed for 2 hr. The obtained solid was filter off, and washed with water and 
purified by recrystalisation from absolute ethanol.  
 
Synthesis of Compound D1 
Compound D
DMSO, Ethanol &  ∆  10  hrs
NH2 NH NH2
S
Compound D 1
N
H
CH3 CH3
NH
O
NH
O
NH
NH2
S
NHS
NH2
CH3
N
H
CH
3
CH
3
OEt
O
EtO
O
CH3
 
Chemicals Required 
Compound D  - 0.1 mole 
Thiosemicarbazide - 0.1 mole 
DMSO   - 5 ml 
Ethanol  - 10ml 
 
Procedure 
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 Equal molar weight of compound D and thiosemicarbazide dissolved in 
ethanol then add 5 ml of DMSO. It was the heated under reflux for 10 hr. The solid 
was obtained, after cool and pour it into crushed ice. The solid was collected by 
filtration, washed with water and purified by re-crystallization with ethanol.  
 
Synthesis of Compound D2 
Compound D
DMSO, Ethanol &  ∆  10  hrs
NH2 NH NH2
O
Compound D 2
N
H
CH
3
CH
3
OEt
O
EtO
O
CH3
N
H
CH3 CH3
NH
O
NH
O
NH
NH2
O
NHO
NH2
CH3
 
 
Chemicals Required 
Compound D  - 0.1 mole 
Semicarbazide  - 0.1 mole 
DMSO   - 5 ml 
Ethanol  - 10ml 
 
Procedure 
Equal molar weight of compound A and semicarbazide dissolved in ethanol then add 
5 ml of DMSO. It was the heated under reflux for 10 hr. The solid was obtained, after 
cool and pour it into crushed ice. The solid was collected by filtration, washed with 
water and purified by re-crystallization with ethanol.  
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Synthesis of Compound E 
CH 3
EtO
O
O
+
CH 3
OEt
O
O
NH 4OAc
Ethyl acetoacetate Ammonium acetate
Reflux up to 2 Hrs
N
H
CH 3CH 3
OEt
O
EtO
O
OCH 3
Compound E
CHO
OCH 3
P - Methoxy Benzaldehyde
 
 
Chemicals Required 
Ethylacetoacetate   -0.2 mole 
Ammonium acetate   -0.1 mole 
Para- Methoxy Benzaldehyde  -0.1 mole 
Procedure 
A reaction mixture was made up of ethylacetoacetate (0.2 mol), Ammonium acetate( 
0.1 mol) para-methoxy benzaldehyde (0.1 mol) in ethanol. It was then heated refluxed 
for 2 hr. The obtained solid was filter off, and washed with water and purified by 
recrystalisation from absolute ethanol.  
Synthesis of Compound E1 
Compound E
DMSO, Ethanol &  ∆  10  hrs
NH2 NH NH2
S
Compound E 1
N
H
CH3 CH3
NH
O
NH
O
NH
NH2
S
NHS
NH2
OCH3
N
H
CH
3
CH
3
OEt
O
EtO
O
OCH3
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Chemicals Required 
Compound E  - 0.1 mole 
Thiosemicarbazide - 0.1 mole 
DMSO   - 5 ml 
Ethanol  - 10ml 
 
Synthesis 
Equal molar weight of compound E and thiosemicarbaside dissolved in ethanol then 
add 5 ml of DMSO. It was the heated under reflux for 10 hr. The solid was obtained, 
after cool and pour it into crushed ice. The solid was collected by filtration, washed 
with water and purified by re-crystallization with ethanol.  
Synthesis of Compound E2 
Compound E
DMSO, Ethanol &  ∆  10  hrs
NH2 NH NH2
O
Compound E 2
N
H
CH
3
CH
3
OEt
O
EtO
O
OCH3
N
H
CH3 CH3
NH
O
NH
O
NH
NH2
O
NHO
NH2
OCH3
 
Chemicals Required 
Compound E  - 0.1 mole 
Semicarbazide  - 0.1 mole 
DMSO   - 5 ml 
Ethanol  - 10ml 
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Procedure: 
Equal molar weight of compound E and semicarbazide dissolved in ethanol then add 
5 ml of DMSO. It was the heated under reflux for 10 hr. The solid was obtained, after 
cool and pour it into crushed ice. The solid was collected by filtration, washed with 
water and purified by re-crystallization with ethanol.  
Thin layer Chromatography  
Purity of the compounds was checked by thin layer chromatography using 
silica gel G as stationary phase and various combinations of ethyl acetate and 
chloroform (2:1) mobile phase. The spots resolved were visualized in UV chamber or 
Iodine vapour. 
Instrumentation: 
The techniques employed for the characterization of the synthesized 
compounds were IR spectra, 
1
H-NMR spectra, Mass spectra. 
 
Infrared Spectra: 
The IR spectra of the synthesized compounds were recorded on a Fourier 
Transform IR spectrometer (Perkin-Elmer) in the range of 4000 – 450 cm
-1
 Nujol 
mull technique and the values are reported. 
 
Nuclear Magnetic Resonance Spectra (
1
H-NMR): 
1
H-NMR spectra were recorded on Bruker – NMR 400 MHz using (CD3)2SO 
and chemical shifts were reported in parts per million (δ ppm). 
 
Mass Spectra- m/e peak. 
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Biological Evaluation 
Anti-Diabetic action 
The study was done in the Central animal house , Madurai Medical College, Madurai 
after getting approval by Institutional Animal Ethical Committee of Madurai Medical 
College, Madurai,  for a period of 3 months. 
Animals 
 Inbred male albino rats from central animal house Madurai Medical College 
were utilized in this study. Each weighing 200 to 250 grams were included in the 
study. Animals were allowed standard diet and tap water ad libitum. 
Each group of animals were housed separately with a distinct identity for each 
animal throughout the study. The diabetic rats were given special care. The floor of 
cages were filled with thick layer of sawdust and it was changed daily. The diabetic 
rats were given adequate food pellets and plenty of water by providing two water 
bottles as the diabetic rats will have polyphagia, polyuria and polydipsia. The bottles 
were filled with fresh tap water every morning. 
Oral acute toxicity studies 
Acute toxicity study is generally carried out for the determination of LD50 
value in experimental animals. The LD50 determination was done in mice by OECD 
guidelines 423. The aim of performing acute toxicity study is for establishing the 
therapeutic index of a particular drug and to ensure the safety in vivo. 
 
 
 
                                                                                                       Biological Evaluation   
 
Dept. of Pharmaceutical Chemistry, Madurai Medical College Page 61 
 
Table-5: Compound : C1 
S. No Number of animals Dose No. of  death 
of animals 
1 3 5 mg/kg  0 
2 3 50 mg/kg 0 
3 3 300 mg/kg 0 
4 3 1000 mg/kg 2* 
*Dose is repeated to confirm LD50 
Table-6: Compound : D1 
S. No Number of animals Dose No. of  death 
of animals 
1 3 300 mg/kg 0 
2 3 1000 mg/kg 2* 
*Dose is repeated to confirm LD50 
Table-7 Physiology of animals 
Parameter  
Animal No:1 Animal No:2 Animal No:3 
Eye ball 
movement 
+ + + 
Salivation - - - 
Muscle strength + + + 
Diarrhea - - - 
Frequent 
urination 
- - - 
Farness - - - 
Body 
temperature 
Optimum Optimum Optimum 
Respiration Normal  Normal  Normal  
vagueness - - - 
hyperactive + - + 
Insomnia - - - 
Nasal discharge  + - - 
 
 
 
 
 
 
                                                                                                       Biological Evaluation   
 
Dept. of Pharmaceutical Chemistry, Madurai Medical College Page 62 
 
Hypoglycemic activity: 
Materials used for the study 
1. Male Albino Rats  
2. Alloxan Monohydrate  
3. Glibenclamide ( Sonafi- Aventis)  
4. Synthetic drug ( 1,4 DHP derivatives) 
5. Carboxy Methyl Cellulose (CMC 1% solution) 
6. Blood glucometer and glucostrips ( Acu-Check Active) 
7. Oral feeding tube with syringe. 
Experimental Design 
Each group consisting of six rats. 
Group I - Control rats received vehicle solution (1% CMC) 
Group II - Diabetic control rats received vehicle solution (1%CMC) 
Group III & IV- Diabetic rats treated with Compound-C1, 50 & 100mg/kg body 
weight in (1% CMC), respectively 
Group V & VI- Diabetic rats treated with Compound-D1, 50 & 100mg/kg body 
weight in (1% CMC), respectively 
Group VII - Diabetic rats treated with standard drug Glibenclamide 0.25 mg/kg body 
weight in aqueous solution. 
The vehicles and the drugs were administered orally using oral intubation tube daily 
for three weeks. Blood samples were collected for the measurement of blood glucose 
level from the tail vein on 0 day, 2
nd
 , 5
th
  and 7
th
  day. The blood glucose level was 
determined by glucometer (one touch). The values of sample treated were compared 
with that of the standard group which was treated with Glibenclamide. Then the 
animals were sacrificed by cervical dislocation.  
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The collected blood samples were immediately centrifuged at 2500 rpm for 15 min. 
The serum separated and analyzed by using auto analyzer. 
 
Diabetic Induced Rat 
 
 
S. No Groups 
1 Drug C1 
2 Drug D1 
3 Standard  
4 Positive control 
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In vitro Evaluation of Antibacterial Activity of Synthesized Compounds: 
Preliminary Antibacterial  & Antifungal Activity: 
Evaluation Methods: 
The antibacterial activity can be evaluated by the following techniques. 
 a)  Agar streak dilution method 
b)  Serial dilution method 
c)  Agar diffusion method 
(i)   Cup plate method 
(ii)  Cylinder method 
(iii) Paper disc method 
       d)  Turbidimetry method 
Diffusion technique is widely used to carry out sensitivity test for pathogenic 
microorganism. Literature reviews reveals that substituted 1, 4 DHPs exhibited pronounced 
antimicrobial activity. The antimicrobial activity was evaluated by measuring the zone of 
inhibition in mm.   
This test shows an idea about the usefulness of different antimicrobial agents when 
used at the usual therapeutic doses. It gave a very approximate measure of the degree of 
sensitivity, when compared to the standard. 
 
Bacteria- Standard Drug Selection: 
 
N
COOHF
N
NH
O
      
Ciprofloxacin
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Ciprofloxacin: 
Chemically it is 1-cyclopropyl-6-fluro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline 
carboxylic acid. 
 It is used as a prototype drug against wide range of microorganism  
 It is a broad spectrum antibiotic 
Mechanism: 
The fluroquinolines are rapidly bactericidal as a consequence of inhibition of DNA 
gyrase and Topoisomerase IV. It is important for gram positive and DNA gyrase is important 
for gram negative bacteria. 
Advantages: 
 Rapid bactericidal activity and  high potency 
 Long post antibiotic effect on entrobacteriaceae 
 Low frequency of mutation 
 Active against many β-lactam and aminogycoside resistant bacteria. 
 
Fungal - Standard Drug Used: 
 
Ketoconazole (KTZ): 
1. It is an imidazole derivative 
2. It is a broad spectrum anti fungal agent (or) antibiotic 
 
O
O
N
N
O
N
N CH3
O
Cl
Cl
Ketaconazole
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Mechanism: 
They inhibit the fungal cytochrome P450 enzyme lanosterol 14-demethylase and 
thus impair ergosterol synthesis leading to a cascade of membrane abnormalities in the 
fungus. 
Advantages 
∇ Both orally and topically  used 
∇ Less toxicity 
∇ Greater efficacy 
∇ Alternative to griseofulvin 
Organisms Used: 
Gram Positive Organism:  
 Staphylococcus epidermidis  
 Streptococcus aurus  
 Streptococcus albus 
Gram Negative Organism:   
 Escherichia coli    
 Proteus 
 Salmonellatyphi 
 Shigella 
 Chromobacterium violaceum 
 Xanthomonas 
Fungai: 
 Candida albicans 
Solvent- DMSO 
Bacterial Medium- Nutrient Agar Medium ( pH: 7.6 ± 0.2)  
Composition: 
1. Beef extract  - 10 gm 
2. Peptone  - 10 gm 
3. Sodium chloride - 5 gm 
4. Agar   - 1-2 % 
5. Water   - 100 ml 
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Procedure 
All the ingredients mixed together and dissolve with 100 ml of distilled water in 
conical flask. The PH was adjusted 7.6 ± 0.2 and sterilized in an autoclave at 120ºC for 15 
min.  
Fungal medium- Sabouraud dextrose agar media ( pH: 5.6±0.2) 
1. Dextrose    - 4 gm 
2. Mixture of equal part of  
( Digest animal tissue +   - 1 gm 
Pancreatic digest of casein )   
3. Agar     - 1.5 gm 
4. Water     - 100 ml 
Procedure 
 All the ingredients mixed together and dissolve with 100 ml of distilled water in 
conical flask. The PH was adjusted 5.6±0.2 and sterilized in an autoclave at 120ºC for 15 min.  
 
Experimental Procedure 
A suspension of the micro-organism was added to sterile nutrient agar medium at 
45
o
C. The mixture was transferred to sterile petri dishes and allowed to solidify. Sterile disc 5 
mm in diameter made from Whatmann No.1 filter paper which is previously sterilized in UV 
lamp was dipped in solution of different concentrations of compound, standard and a blank 
were placed on the surface of agar plates. 
The plates to keep for 1 h at room temperature as a period of   pre-incubation to 
minimize the effects of variation in time between the applications of the different solutions. 
Then the plate were incubated for 24 h (for Candida albicans 48 h) at 37 ± 1
o
C and observed 
for antibacterial activity. The diameter of zone of inhibition was observed and recorded. 
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Results & Discussion 
Table:8 
Comp Molecular 
weight 
Log P Drug 
Likeness 
Drug  
Score
 
A1 357.465 -0.047 6.34 0.86 
B1 419.536 1.275 6.22 0.72 
C1 435.53 0.796 6.25 0.73 
D1 433.56 1.723 4.63 0.67 
E1 449.56 1.331 6.07 0.69 
A2 325.32 -1.129 6.81 0.89 
B2 387.40 0.193 6.70 0.77 
C2 403.39 -0.286 6.71 0.78 
D2 401.42 0.642 5.1 0.72 
E2 417.41 0.25 6.51 0.74 
 
Table 9: Lipinski properties of the synthesized compounds  
Comp Molecular 
weight 
Log P H bond 
donor 
H bond 
acceptor 
Molar 
refractivity 
Number of 
criteria met 
 
rule < 500 <5 <5 <10 40-130 At least 3 
A1 357.465 -0.047 9 9 94.16 4 
B1 419.536 1.275 9 9 113.89 4 
C1 435.53 0.796 10 10 115.77 4 
D1 433.56 1.723 9 9 118.72 4 
E1 449.56 1.331 9 10 120.57 4 
A2 325.32 -1.129 9 11 79.64 3 
B2 387.40 0.193 9 11 99.37 3 
C2 403.39 -0.286 10 12 101.26 3 
D2 401.42 0.642 9 11 104.20 3 
E2 417.41 0.25 9 12 106.05 3 
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Table-10: Analytical Data for compounds 
Compound Nature of 
the crystals 
% 
 yield 
Melting 
Point(
0
C) 
Soluble  
in 
Molecular 
Formula 
Molecular 
weight 
A1 White solid 73 210 DMSO C12H19N7O2S2 
 
357.45 
B1 White solid 78 220 DMSO C17H21N7O2S2 
 
 
419.52 
 
C1 White solid 74 211 DMSO C17H21N7O3S2 
 
 
435.52 
D1 White solid 62 240 DMSO C18H23N7O2S2 
 
 
433.55 
 
 
E1 White solid 59 201 DMSO C18H23N7O3S2 
 
 
449.55 
 
A2 Yellowish  
Gummy 
solid 
65 190 DMSO C12H19N7O4 
 
 
325.32 
 
B2 Yellowish  
Gummy 
solid 
61 197 DMSO C17H21N7O4 
 
 
387.39 
 
C2 Yellowish  
Gummy 
solid 
69 191 DMSO  
C17H21N7O5 
 
 
 
403.39 
 
D2 Yellowish  
Gummy 
solid 
66 187 DMSO C18H23N7O4 
 
 
401.41 
 
E2 Brown solid 67 220 DMSO C18H23N7O5 
 
 
417.44 
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Table:11 List of synthesized Compounds its IUPAC Name 
S. NO Compounds IUPAC Name 
A1  
 
 
2,2'-[(2,4,6-trimethyl-1,4-dihydropyridine-
3,5diyl) dicarbonyl] dihydrazine 
carbothioamide 
 
 
B1 
 
 
 
2,2'-[(2,6-dimethyl-4-phenyl-1,4-
dihydropyridine-3,5 diyl) dicarbonyl] 
dihydrazine carbothioamide 
 
 
C1 
 
 
 
2,2'-{[4-(4-hydroxyphenyl)-2,6-dimethyl-1,4-
dihydropyridine-3,5-diyl]dicarbonyl} 
dihydrazine carbothioamide 
 
D1 
 
 
 
 
 
 
2,2'-{[4-(4-methyl phenyl)-2,6-dimethyl-1,4-
dihydropyridine-3,5-diyl] dicarbonyl} 
dihydrazinecarbothioamide 
 
 
E1 
 
 
 
 
 
 
 
 
2,2'-{[4-(4-methoxy phenyl)-2,6-dimethyl-
1,4-dihydropyridine-3,5diyl]dicarbonyl} 
dihydrazine carbothioamide 
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S.No Compounds IUPAC Name 
A2 
 
 
 
2,2'-[(2,4,6-trimethyl-1,4-dihydropyridine-
3,5-diyl)dicarbonyl]dihydrazinecarboxamide 
 
B2 
 
 
 
 
2,2'-[(2,6-dimethyl-4-phenyl-1,4-
dihydropyridine-3,5-
diyl)dicarbonyl]dihydrazinecarboxamide 
 
C2 
 
 
 
2,2'-{[4-(4-hydroxyphenyl)-2,6-dimethyl-1,4-
dihydropyridine-3,5-
diyl]dicarbonyl}dihydrazinecarboxamide 
 
D2 
 
 
 
 
 
 
2,2'-{[4-(4-methyl phenyl)-2,6-dimethyl-1,4-
dihydropyridine-3,5-
diyl]dicarbonyl}dihydrazinecarboxamide 
 
E2 
 
 
 
 
 
 
 
 
 
 
2,2'-{[4-(4-methoxy phenyl)-2,6-dimethyl-
1,4-dihydropyridine-3,5-diyl]dicarbonyl} 
dihydrazinecarboxamide 
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Table-12: Elemental Composition of synthesized compounds 
 
 
 
 
 
 
 
 
 
 
 
Table-13 Rf Value of synthesized compounds 
Compounds Rf Value 
A1 0.83 
B1 0.72 
C1 0.78 
D1 0.65 
E1 0.81 
A2 0.80 
B2 0.75 
C2 0.72 
D2 0.70 
E2 0.84 
 
Compounds Elemental Composition in Percentage (%) 
C H N O S 
A1 40.32 5.36 27.43 8.95 19.94 
B1 48.67 5.05 23.37 7.63 15.29 
C1 46.88 4.86 22.51 11.02 14.72 
D1 49.87 5.35 22.61 7.38 14.79 
E1 48.09 5.16 21.81 10.68 14.27 
A2 44.30 5.89 30.14 19.67 - 
B2 52.71 5.46 25.31 16.52 - 
C2 50.26 5.25 24.31 19.83 - 
D2 53.68 5.78 24.43 15.94 - 
E2 51.79 5.55 23.49 19.16 - 
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Table-14: Infra Red spectral study of the complexes synthesized Compound 
Compounds Spectral 
peaks(cm
-1
) 
Molecular nature 
A1  
 
3334  
1719 
1233 
1044 
771 
-NH stretching  
-C=O stretching (ketone) 
-C=S stretching 
-C-N vibrational 
-C-H (bending atomatic) 
B1 
 
3343 
3237 
3060  
2982 
1688  
1248 
-NH stretching  
-NH-C=O streching 
-CH-CH stre. (aromatic)  
-C-H  stret. (methyl) 
-C=O stretching (ketone) 
-C=S stretching  
 
C1  
 
3342 
3184  
1579  
1248 
1093  
-O-H stretching   
-NH-C=O stretching 
-C=C stre. (aromatic)  
-C=S stretching  
-N-C-N bending  
D1 
 
 
 
 
3359 
2986 
1696 
1653 
1093 
-NH stretching 
-CH-CH- stret. Aromatic 
-C=O stret. (ketone) 
-C=S stretching 
-N-C-N bending 
E1 
 
 
 
 
 
 
3241 
3097 
1690 
1651 
1609 
-NH stretching 
-CH-CH- stret. (Aromatic) 
-C=O stret. (ketone) 
-C=S stretching 
-N=N- bending  
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Compounds Spectral 
peaks(cm-1) 
Molecular nature 
A2 
 
3432 
2923  
1721 
1654 
1224 
-NH2 stretching  
-CH stretching( methyl)   
-C=O stretching (ketone) 
-C=O stretching (ester) 
-N-C-N bending  
B2 3342  
3090  
1689 
1651 
1091  
-NH stretching  
-CH-CH stre. (aromatic)  
-C=O stretching  
-N=N- stretching 
-N-C-N bending 
 
C2  
3321  
2936 
1718  
1597  
1097 
 
>C=O—H(bonded) stret.  
-CH-CH stre. (aromatic)  
-C=0 stretching (ester) 
-N=N stretching  
-N-C-N bending 
D2 
 
 
 
 
3214 
2986 
1689 
1076 
NH-C=O stretching  
-CH-CH stre. (aromatic)  
-C=0 stretching (ester) 
-N-C-N bending 
E2 
 
 
 
 
 
 
 
3342 
2980 
1689 
1118 
834 
-NH stretching  
-CH-CH stret. (aromatic)  
-C=0 stretching (ketone) 
-N-C-N bending 
-C-H bending (aromatic) 
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Compound-A1 
 
Compound-B1 
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Compound-C1 
 
Compound-D1 
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Compound-E1 
 
 
Compound-A2 
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Compound-B2 
 
Compound-C2 
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Compound-D2 
 
Compound-E2 
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Table-15 
1
H NMR Spectral data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound  
 
Chemical Shift value  
 
Proton nature  
 
A1 
 
 
 
11.53 
8.17 
7.09 
3.83 
2.28 
s, H, -NH  
s, 1H, NH of Pyridine ring 
m, 5H, Ar-H  
s, 2H, N-CH2 
s, 6H, C2-CH3 & C6-CH3 
B1 
 
 
 
 
11.58 
8.14 
6.83 
3.83 
2.28 
s, H, -NH  
s, 1H, NH of Pyridine ring 
m, 5H, Ar-H  
s, 2H, N-CH2 
s, 6H, C2-CH3 & C6-CH3 
C1  
 
13.25 
8.40 
7.27 
3.88 
2.28 
s, H, -NH  
s, 1H, NH of Pyridine ring 
m, 5H, Ar-H  
s, 2H, N-CH2 
s, 6H, C2-CH3 & C6-CH3 
D1 
 
 
 
 
11.73 
8.27 
7.17 
3.90 
2.18 
s, H, -NH  
s, 1H, NH of Pyridine ring 
m, 5H, Ar-H  
s, 2H, N-CH2 
s, 6H, C2-CH3 & C6-CH3 
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1
H NMR Spectral data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound  
 
Chemical Shift value  
 
Proton nature  
 
E1 
 
 
 
11.52 
8.30 
7.18 
3.83 
2.28 
s, H, -NH  
s, 1H, NH of Pyridine ring 
m, 5H, Ar-H  
s, 2H, N-CH2 
s, 6H, C2-CH3 & C6-CH3 
A2  
 
 
 
 
11.98 
8.14 
7.13 
3.63 
2.30 
s, H, -NH  
s, 1H, NH of Pyridine ring 
m, 5H, Ar-H  
s, 2H, N-CH2 
s, 6H, C2-CH3 & C6-CH3 
B2  
 
11.91 
8.07 
7.17 
3.70 
2.95 
s, H, -NH  
s, 1H, NH of Pyridine ring 
m, 5H, Ar-H  
s, 2H, N-CH2 
s, 6H, C2-CH3 & C6-CH3 
C2  
 
 
 
 
11.90 
8.13 
7.10 
3.73 
2.74 
s, H, -NH  
s, 1H, NH of Pyridine ring 
m, 5H, Ar-H  
s, 2H, N-CH2 
s, 6H, C2-CH3 & C6-CH3 
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1
H NMR Spectral data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound  
 
Chemical Shift value  
 
Proton nature  
 
D2 
 
 
 
11.42 
8.09 
7.26 
3.28 
2.58 
s, H, -NH  
s, 1H, NH of Pyridine ring 
m, 5H, Ar-H  
s, 2H, N-CH2 
s, 6H, C2-CH3 & C6-CH3 
E2  
 
 
 
 
11.97 
8.14 
7.13 
3.39 
2.54 
s, H, -NH  
s, 1H, NH of Pyridine ring 
m, 5H, Ar-H  
s, 2H, N-CH2 
s, 6H, C2-CH3 & C6-CH3 
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NMR Spectra 
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14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm
2.
07
7
6
2.
28
96
2.
50
7
4
2.
51
16
2.
51
57
3.
26
34
3.
83
40
6.
97
54
6.
98
39
6.
99
02
6.
99
87
7
.
08
56
7
.
09
50
7
.
10
7
0
7
.
11
85
7
.
12
63
7
.
49
20
7
.
51
20
7
.
75
96
8.
17
47
11
.
55
32
3.
58
2.
44
1.
00
3.
35
2.
36
1.
20
1.
13
Current Data Parameters
NAME         Jan13-2012
EXPNO                10
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.17
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  203
DW               41.600 usec
DE                 6.00 usec
TE                292.4 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
SRINIVASAN-1
BRUKER
AVANCE II 400 NMR
Spectrometer
SAIF
Panjab University
Chandigarh
avtar_saifpu@yahoo.co.in  
6.97.07.17.27.37.47.57.67.77.87.98.08.18.28.3 ppm
6.
97
54
6.
98
39
6.
99
02
6.
99
87
7.
08
56
7.
09
50
7.
10
70
7.
11
85
7.
12
63
7.
49
20
7.
51
20
7.
75
96
8.
17
47
1.
00
3.
35
2.
36
1.
20
Current Data Parameters
NAME         Jan13-2012
EXPNO                10
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.17
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  203
DW               41.600 usec
DE                 6.00 usec
TE                292.4 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
SRINIVASAN-1
BRUKER
AVANCE II 400 NMR
Spectrometer
SAIF
Panjab University
Chandigarh
avtar_saifpu@yahoo.co.in  
                                                                                                             Results & Discussion 
 
Dept. of Pharmaceutical Chemistry, Madurai Medical College Page 84 
 
1.82.02.22.42.62.83.03.23.43.63.84.04.24.4 ppm
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Compound C1 
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2.62.83.03.23.43.63.84.04.24.44.64.85.0 ppm
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SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
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Compound D1 
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Current Data Parameters
NAME         Jan13-2012
EXPNO                40
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.32
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  256
DW               41.600 usec
DE                 6.00 usec
TE                292.4 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1299797 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
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6.97.07.17.27.37.47.57.67.77.87.98.08.18.28.38.48.5 ppm
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Current Data Parameters
NAME         Jan13-2012
EXPNO                40
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.32
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  256
DW               41.600 usec
DE                 6.00 usec
TE                292.4 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1299797 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
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7.007.057.107.157.207.257.307.357.407.457.507.557.607.657.707.75 ppm
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Current Data Parameters
NAME         Jan13-2012
EXPNO                40
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.32
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  256
DW               41.600 usec
DE                 6.00 usec
TE                292.4 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1299797 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
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Compound E1 
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Current Data Parameters
NAME         Jan13-2012
EXPNO                50
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.37
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  287
DW               41.600 usec
DE                 6.00 usec
TE                292.4 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1299710 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
SRINIVASAN-5
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Compound A2 
16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm
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Current Data Parameters
NAME         Jan13-2012
EXPNO                60
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.42
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  256
DW               41.600 usec
DE                 6.00 usec
TE                292.5 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1299831 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
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6.946.966.987.007.027.047.067.087.107.127.147.167.187.207.22 ppm
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Current Data Parameters
NAME         Jan13-2012
EXPNO                60
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.42
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  256
DW               41.600 usec
DE                 6.00 usec
TE                292.5 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1299831 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
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Compound B2 
15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm
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Current Data Parameters
NAME         Jan13-2012
EXPNO                70
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.47
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  362
DW               41.600 usec
DE                 6.00 usec
TE                292.5 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1299749 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
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6.76.86.97.07.17.27.37.47.57.67.77.87.98.08.18.2 ppm
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Current Data Parameters
NAME         Jan13-2012
EXPNO                70
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.47
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  362
DW               41.600 usec
DE                 6.00 usec
TE                292.5 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1299749 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
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2.02.22.42.62.83.03.23.43.63.84.04.2 ppm
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Current Data Parameters
NAME         Jan13-2012
EXPNO                70
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.47
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  362
DW               41.600 usec
DE                 6.00 usec
TE                292.5 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1299749 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
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Compound C2 
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm
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Current Data Parameters
NAME         Jan13-2012
EXPNO                80
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.52
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  575
DW               41.600 usec
DE                 6.00 usec
TE                292.6 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
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6.26.46.66.87.07.27.47.67.88.08.28.48.6 ppm
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Current Data Parameters
NAME         Jan13-2012
EXPNO                80
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.52
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  575
DW               41.600 usec
DE                 6.00 usec
TE                292.6 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
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2.83.03.23.43.63.84.04.24.44.64.85.05.2 ppm
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NAME         Jan13-2012
EXPNO                80
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.52
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  575
DW               41.600 usec
DE                 6.00 usec
TE                292.6 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
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6.957.007.057.107.157.20 ppm
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Current Data Parameters
NAME         Jan13-2012
EXPNO                80
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.52
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  575
DW               41.600 usec
DE                 6.00 usec
TE                292.6 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
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Compound D2 
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Current Data Parameters
NAME         Jan13-2012
EXPNO                90
PROCNO                1
F2 - Acquisition Parameters
Date_          20120113
Time              13.57
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT            DMSO
NS                    8
DS                    2
SWH           12019.230 Hz
FIDRES         0.183399 Hz
AQ            2.7263477 sec
RG                  406
DW               41.600 usec
DE                 6.00 usec
TE                292.6 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.90 usec
PL1               -3.00 dB
SFO1        400.1324710 MHz
F2 - Processing parameters
SI                32768
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Compound E2 
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Table: 16 
MASS Spectral study of the compounds synthesized: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Molecular ion peak 
S-1 357.45(358) 
 
S-2 419.52(421) 
 
S-3 435.52(437) 
 
S-4 433.55(435) 
 
S-5 449.55(451) 
 
S-6 325.32(329) 
 
S-7 387.39(389) 
 
S-8 403.39(407) 
 
S-9 401.41(411) 
 
S-10 417.44(424) 
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Compound-A1 
 
 
Compound-B1 
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Compound-C1 
 
 
Compound-D1 
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Compound-E1 
 
Compound-A2 
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Compound-B2 
 
 
Compound-C2 
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Compound-D2 
 
 
Compound-E2 
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Table-17: % Reduction of Blood Glucose Level 
Groups Treatment/Dose 
Blood glucose level (mg/dcl) % Reduction in glucose 
level on 7th day Normal 0 day 2nd day 5th day 7th day 
Normal Control 1% CMC, 10 ml/kg 96.66±3.87 96.66±3.71 96.66±3.35 93.66±3.41 99.33±5.98 0 
Positive Control 1% CMC, 10 ml/kg 100.66±1.85 204±4.86 215±3.08 230.16±5.19 247.16±6.21 0 
Standard 
Glybenclamide 
0.25 mg/kg 107.33±4.02 264.16±11.51 133.5±2.72 127.83±5.7 113.66±3.42 56.97** 
Compound-C1 50 mg/kg B.W 105.66±3.32 298.83±2.83 223.5±11.30 208.33±9.21 193.5±10.44 34.37** 
Compound-C1 100 mg/kg B.W 106±2.35 297.33±6.51 282.16±6.23 264.5±6.04 257.16±7.76 13.5*** 
Compound-D1 50 mg/kg B.W 112.33±4.33 303.66±6.59 286.83±9.53 279.5±9.82 272.5±11.11 10.24*** 
Compound-D1 100 mg/kg B.W 107.83±4.15 293.66±7.43 280±6.26 271.66±6.18 260.66±4.17 11.24*** 
n=6, Results were presented as mean ± standard error of mean (SEM) and the statistical analysis was done using one way analysis of variance 
(ANOVA). A p-value of p < 0.01 was considered to be statistically significant. 
** P<0.01;  *** P<0.1 
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Figure-2 
 
Figure-3 
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Table-18: Serum profile of experimental animals 
Groups Treatment/Dose 
Biochemical parameters 
Serum 
 Urea 
(mg/dl) 
Serum  
Creatinine 
(mg/dl) 
Serum  
Cholesterol  
(mg/dl) 
Serum 
protein 
(g/dl) 
Normal  
Control 
1% CMC, 10 
ml/kg 30.09±1.09 0.52±0.02 104.60±2.02 6.17±0.16 
Positive  
Control 
1% CMC, 10 
ml/kg 60.42±1.02 1.47±0.04 178.80±1.36 4.71±0.92 
Standard 
Glybenclimide 
0.25 mg/kg 32.18±1.24 0.64±0.02 127.9±2.15 6.20±0.22 
Com-C1 50 mg/kg B.W 37.33±0.64* 0.72±0.02* 132±2.64* 5.56±0.02 
Com-C1 100 mg/kg B.W 59.24±1.48 1.29±0.02 170.4±6.26 4.57±0.13 
Com-D1 50 mg/kg B.W 52.47±1.64 0.94±0.02 161±2.20 5.86±0.20 
Com-D1 100 mg/kg B.W 44.21±1.82 0.91±0.02 147.00±2.68 5.72±0.15 
Results were presented as mean ± standard error of mean (SEM), n=6, P<0.01 
*Test is significant with standard   
Figure- 
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Table:19 Anti-Microbial activity( Zone of inhibition) 
                         Gram Postive                                                  Gram Negative       Fungal 
Compound Dose S. epi S. aurus S. albus E. coli Proteus S. thphi Shigella A. violaceum X. monas C. albicans 
A1 
Control 6 8 5 10 7 6 6 7 9 6 
Standard 18 14 12 30** 18 25 18 16 18 17 
500 mcg 12 13 8 17 10 8 12 10 12 14 
1000 mcg 15 13 10 23** 12 14 14 11 15 14 
1500 mcg 14 12 9 20 15 14 12 14 15 15 
2000 mcg 15 12 10 20 17 15 10 14 14 15 
B1 
Control 6 7 9 6 10 6 8 9 6 7 
Standard 22 18** 16 24 19 21 15 19 26 12 
500 mcg 11 14 9 12 12 6 12 10 17 8 
1000 mcg 14 17** 13 15 12 9 16 14 19 7 
1500 mcg 15 15 15 15 13 7 17 16 20 9 
2000 mcg 15 15 12 16 14 8 15 16 20 10 
C1 
Control 8 6 7 9 6 7 6 11 8 12 
Standard 28 31 22 29** 24 27 29 23 20 24 
500 mcg 15 16 19 22 18 12 14 13 12 15 
1000 mcg 24 8 15 25** 16 12 17 17 12 16 
1500 mcg 22 12 19 19 19 14 14 19 14 13 
2000 mcg 22 12 20 22 20 16 12 20 17 13 
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                         Gram Postive                                                  Gram Negative       Fungal 
Compound Dose S. epi S. aurus S. albus E. coli Proteus S. thphi Shigella A. violaceum X. monas 
C. 
albicans 
D1 
Control 8 7 10 6 9 8 6 10 11 10 
Standard 32 24 27 30 27** 29 28 30 25 29 
500 mcg 16 12 16 17 14 11 16 18 15 16 
1000 mcg 19 15 17 19 16 14 19 14 19 20 
1500 mcg 22 17 20 18 17 15 20 14 22 23 
2000 mcg 20 18 20 18 24** 17 23 15 22 25 
E1 
Control 9 7 11 8 10 6 9 6 10 8 
Standard 26 29 22 19 24 24 26 24 25 27** 
500 mcg 13 17 14 15 16 12 11 10 11 23** 
1000 mcg 19 19 16 15 15 16 19 14 16 21 
1500 mcg 19 17 17 18 17 14 21 17 19 22 
2000 mcg 21 18 19 17 19 16 20 16 20 23 
A2 
Control 8 9 7 10 7 11 6 8 7 8 
Standard 22 18 20 21 17 19 22 20 17 23 
500 mcg 11 14 13 12 10 11 14 15 10 11 
1000 mcg 14 15 13 13 10 10 16 16 12 13 
1500 mcg 15 14 15 15 12 12 17 18 14 15 
2000 mcg 17 14 17 16 14 12 19 18 13 17 
B2 
Control 7 6 7 9 10 6 6 10 6 8 
Standard 22 20 26 19 21 23 18 16 20 17 
500 mcg 11 12 14 9 13 10 9 11 10 10 
1000 mcg 13 13 16 12 15 12 11 14 13 13 
1500 mcg 12 11 13 10 14 12 15 10 13 14 
2000 mcg 13 11 15 10 14 10 13 11 16 14 
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                         Gram Postive                                                  Gram Negative       Fungal 
Compound Dose S. epi S. aurus S. albus E. coli Proteus S. thphi Shigella A. violaceum X. monas 
C. 
albicans 
C2 
Control 6 8 9 8 10 7 9 10 9 8 
Standard 20 19 22 25 26 29 30 24 22 20 
500 mcg 9 11 10 12 13 14 11 12 13 9 
1000 mcg 13 13 13 10 16 15 13 14 11 12 
1500 mcg 15 16 14 12 15 17 15 16 10 11 
2000 mcg 14 15 13 11 14 19 19 13 14 14 
D2 
Control 7 9 6 9 10 6 8 9 9 8 
Standard 26 26 23 28 21 20 19 24 22 20 
500 mcg 13 12 10 9 13 11 13 12 10 11 
1000 mcg 15 14 12 13 15 14 15 16 15 13 
1500 mcg 14 17 17 15 17 10 15 15 14 10 
2000 mcg 14 19 17 14 15 16 14 14 12 14 
E2 
Control 7 8 10 9 8 10 9 8 10 8 
Standard 24 20 21 19 26 17 22 20 19 18 
500 mcg 11 10 11 12 10 13 10 11 11 10 
1000 mcg 13 14 15 14 13 15 12 10 13 13 
1500 mcg 15 14 18 16 15 15 11 13 16 13 
2000 mcg 17 16 13 18 15 17 15 13 14 16 
 
Note: ** Test is siginificant with Standard  
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Figure-4: Anti-Microbial Activity 
 
               E. coli    Xanthomonas 
 
                            Chromobacterium                                           Shigella 
 
                                         Proteus                                              Salmonella 
                
                                 Strepto cocci                                            Staph. albus 
                
                                    Step. Aurus                                      Candida albicans 
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Discussion 
The molecular design shows that the synthesised compounds were accessed  
for the toxicity prediction and safety marigin by using  
“osrisis property explorer”. It shows the drug likeness and drug score. The results 
were shown in the figure No.1 &  Table-8.  
The ADME property of synthesised compounds were predicted by using  
software tool “Molinspiration”.  
Lipinski Rule 5 were predicted for the synthesised compounds, compound A1, 
B1, C1, D1& E1 shows only one violation in basic properties. Compound A2, B2, C2, 
D2 & E2 shows two violation in basic properties. The results were shown in the table 
No-9. 
The new series of 1,4 DHPs have been prepared from  aldehydes, 
ethylacetoacetate & ammonium acetate by Hantzsch method. From the intermediate 
compounds A, B, C, D & E were reacted with thiosemicarbazide  to give compound 
A1, B1, C, D1,  E1 and react with semicarbazide to give compounds A2, B2, C2, D2 
& E2. The physical data of synthesised were determined and results were shown in 
the table-10. The strucuture of synthesised compounds were confirmed by FTIR, 1 H 
NMR & Mass spectra. The results were shown in the table  No-14,15 &16. 
According to literature review and SAR of 1, 4 DHPs reveals that, substituted 
aromatic group at 4
th
 position significant for biological action. Based on that 
compound C1 & D1 were selected for anti-diabetic action. 
LD50 of the synthesised compounds ( C1&D1) were determined according to 
OECD guideliness 423, the lethality were found at dose 1000 mg/kg b.w. From lethal 
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dose, 1/10 & 1/20 consider as a effective dose. The results were shown in the table  
No- 5 &6. 
Pancreas is the primary organ involved in sensing the organism’s dietary and 
energetic states via glucose concentration in the blood and in response to elevated 
blood glucose, insulin is secreted. However, alloxan causes diabetes through its ability 
to destroy the insulin-producing -cells of the pancreas. When there are not enough 
available beta-cells to supply sufficient insulin to meet the needs of the body, insulin-
dependent diabetes results .The cytotoxic action of alloxan is mediated by reactive 
oxygen species with simultaneous massive increase in cytosolic calcium concentration 
leading to rapid destruction of -cells. This results in a decrease in endogenous insulin 
secretion. 
In the present study substituted 1, 4 DHPs ( C1 & D1)  were evaluated anti-
hyperglycemic effect. In the normal fasted rats there was no siginificant 
hypoglycemic effect. 
In alloxan induced diabetic rats revealed that compound C1-100, D1- 50 & 
100 mg/kg b.w., has no siginificant antihyperglycemic effect ( P<0.1) compare with 
standard. But the compound C1 at 50 mg/kg b.w., produced siginificant reduction in 
blood glucose level in compare with standard drug ( glibenclamide) P<0.01. The 
results were shown in the table-17, figure- 2&3. 
Serum profile shows the elevated level in control, test group ( C1-100, D1 -50 
& 100. But it decreases elevated level in test group C1-50 is significant with standard 
group & normal control. The results were shown in the table No-18, Figure-4. 
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Antibacterial activity:  
1, 4 DHPs containing aromatic hydroxyl are well known for their anti-
microbial properties. All 1,4 DHP  derivatives were subjected to anti-microbial assay 
by Disc-diffusion method. The area of zone of inhibition was recorded in mm. All the 
10 derivatives were evaluated for anti-bacterial activity against both gram positive  
and gram negative bacteria. 
In the antibacterial screening of the synthesized compounds most of them 
showed moderate antibacterial activity at various concentrations as compared to the 
standard (Ciprofloxacin). It is seen that these compounds showed some activity 
against gram negative as compared to gram positive microorganisms.  
Gram positive - Compound B1 significant with standard at 500 mcg/ml for S. 
aureus. 
Gram negative - Within the series, C1>A1 (E. coli), D1 (Proteus) significant 
with standard.  
Anti-fungal activity 
The synthesized compounds were subjected to antifungal activity by the disc 
diffusion method. The antifungal activity was evaluated against Candida albicans  
and their zone of inhibition in mm were recorded and compared with the standard 
Ketoconazole. Within the series, the compound E1 shown significant with standard. 
The results were shown in the table No.19 & Figure No-5.   
  
 
 
 
 
 
 
 
 
Summary  
& 
Conclusion 
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Summary & Conclusion 
The main focus of this research work was to synthesize new series of 1,4 
DHPs and look for their better antibacterial and antifungal activity. The yield of the 
newly synthesized DHP series were found to be in the range from 36 to 42%. The 
identification of the structures was ascertained by melting point and TLC. Structure of 
the synthesized compounds were confirmed and characterized with the help of IR, 
1
H-
NMR and mass spectra. 
 The IR data of synthesized new series of 1, 4 DHPs clearly showed the 
presence of functional groups C-S, C=N, N-H, and aromatic rings. The 
1
H-NMR data 
also showed characteristic peaks of NH and Ar H have been confirmed.  
The current study provides some useful insight into the anti-hyperglycemic 
potency of new series of 1,4 DHPs  in alloxan induced diabetes and antimicrobial 
activity of wide range of bacteria and fungi. 
The antibacterial activity of 1,4 DHP derivatives were produced  +
ve
 results. In 
the series of synthesized compounds B1 significant with standard ( G 
+ve
)  and 
compounds A1&C1 were shown greater activity against E. Coli, D1 against proteus. 
The antifungal activity E1 compound showed superior activity.  
However, we suggest that further work should be carried out at molecular 
level to find out the absolute mechanism of action of 1,4 DHPs in experimental 
diabetes and wide range of micro-organisms. 
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